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Abstract 
 
Background. In the last 15 years, it has become increasingly accepted that 
cerebral grey matter (GM) damage in MS is evident since early MS stages and 
provides the best correlate of the rate of clinical progression since early disease 
stages. The lack of substantial inflammatory infiltrates, complement deposition 
and blood brain barrier damage in MS cortical lesions led to the initial suggestion 
that the mechanisms underlying GM and white matter (WM) pathology 
substantially differ and that activated microglia are the dominant effector cell 
population causing GM damage. Furthermore, in the last decade, post-mortem 
studies have revealed that the extent of meningeal inflammation associates 
positively with subpial cortical demyelination and disease progression, 
suggesting that chronic immune activity in the subarachnoid compartment plays 
a key role in mediating damage in the adjacent cerebral cortex of affected 
patients. Factors released by immune cells circulating in the CSF and/or 
colonizing the subarachnoid space may diffuse across the pial membrane, 
inducing a gradient of glia and neuronal pathological alterations, directly and/or 
indirectly through activated microglia.  
Aim of the study. To combine CSF molecular and protein analyses with advanced 
MRI imaging techniques, able to better identify cortical grey matter 
demyelination, in order to identify potential early biomarkers of GM pathology 
and disease progression with prognostic and predictive value and to obtain 
information on the biological and immunological mechanisms that link the 
inflammatory process of the GM and the progressive neurodegeneration 
Methods. Two independent cohorts of MS patients have been recruited and 
followed by the MS Centre of Padova. The first cohort of MS patients, composed 
of 35 patients and 5 controls was recruited retrospectively between February 
2009 and September 2011 and followed by a detailed neurological and clinical 
follow-up. The second cohort of 31 patients and 13 controls was collected 
prospectively from January 2014 to May 2015. The patients, at their disease 
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onset or in the very early phase of the disease, underwent a complete diagnostic 
work-up comprehensive of clinical evaluation, lumbar puncture and MRI 
evaluation inclusive of non-conventional sequences. By using the immuno-assay 
Bio-Plex System technique (Biorad - Bio-Plex Pro Human Chemokine panel 40-
plex) we performed a protein analysis of the presence and levels of inflammatory 
molecules in both cohorts. In the second cohort we carried out also a gene 
expression analysis of the matched cellular fraction (using pre amplification real-
time PCR for a panel of genes of interest). 
Results. CSF protein analysis of the first cohort of MS patients reveal higher 
levels of proinflammatory cytokines CXCL13 (p=0,00006), CCL19 (p=0,0019), CCL1 
(p=0,00018), and CCL22 (0.0009) compared to controls. Protein analysis on our 
second cohort pointed out an important increase of CXCL13, CXCL10, CXCL11 and 
CCL2 in MS population compared to controls. After stratification according to GM 
pathology we reported an increase of CXCL13 protein levels in the MS subgroup 
with higher cortical demyelination. Gene expression analysis reveals a significant 
increase in MS patients for CD20, CD138 and LTa compared to controls 
supporting the hypothesis of a key role of a B-cell response and lymphoid 
neogenesis in MS pathology 
Conclusions. Combined CSF analysis and MRI analysis suggested that B cell 
immune response may play an important role in MS since the disease onset and 
correlates with the level of intrathecal inflammation and cortical pathology. A 
more detailed analysis of the CSF biomarkers suggested in the current study 
might provide, in addition to MRI optimization, a better indication of severity of 
disease process that characterized GM pathology and important tools in 
predicting/monitoring the evolution of the disease. 
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Esposizione riassuntiva in lingua italiana 
 
Presupposti dello studio. Studi istopatologici e neuroradiologici hanno 
dimostrato soprattutto negli ultimi 15 anni come la sclerosi multipla, considerata 
classicamente una patologia elettiva della sostanza bianca, sia una patologia 
caratterizzata da un coinvolgimento,  fin dalle prime fasi di malattia, anche della 
sostanza grigia corticale e profonda che ben correla con il quadro di disabilità 
fisica e cognitiva ampiamente descritto. Dal punto di vista istopatologico tale 
coinvolgimento è caratterizzato dalla presenza di lesioni corticali che si 
distinguono per una minor componente infiammatoria, per un’assenza di danno 
a carico della barriera ematoencefalica e per un minor deposito di fattori del 
complemento. Alla luce di tale descrizione sembra che i meccanismi che 
sottendono il danno a carico della sostanza grigia differiscano almeno in parte da 
quelli osservati a carico della sostanza bianca.   In particolare è stata osservata 
un’associazione tra lesioni corticali e la presenza di infiltrati infiammatori 
meningei correlata ad una maggiore disabilità clinica. È stato quindi evidenziato 
come molecole pro-infiammatorie rilasciate dalle cellule infiammatorie residenti 
nelle meningi diffondano attraverso lo spazio subaracnoideo e agiscano, 
direttamente o indirettamente attivando la componente microgliale, sulla 
adiacente corteccia cerebrale determinando un gradiente di danno corticale. 
Obiettivi. L’obiettivo di questo studio è stato quello di verificare la presenza di 
possibili potenziali biomarcatori  di danno corticale mediante l’applicazione 
combinata di: a) tecniche avanzate di analisi proteica  e analisi molecolare 
applicate allo studio del liquido cerebro spianale; b) tecniche non convenzionali 
di risonanza magnetica in grado di caratterizzare il danno a carico della sostanza 
grigia sia focale che diffuso. 
Materiali e metodi. Sono state arruolate due coorti di pazienti: la prima studiata 
retrospettivamente era composta da 35 pazienti e 5 controlli; la seconda 
arruolata nello studio con un approccio di tipo longitudinale era composta da 31 
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pazienti e 13 controlli. Tutti i pazienti erano caratterizzati da un esordio 
relativamente recente e la precedente somministrazione di terapie 
immunomodulanti rappresentava un criterio di esclusione.  Tutti i pazienti si 
sono sottoposti ad un iter diagnostico completo comprensivo di valutazione 
clinica, esami di laboratorio, esame del liquido cerebrospinale e risonanza 
magnetica comprensiva di sequenze non convenzionali per verificare la presenza 
di lesioni della sostanza grigia. Lo studio del liquido cerebrospinale prevedeva 
inoltre uno studio di analisti proteica mediante immuno-assay (Bio-Plex System 
technique Biorad - Bio-Plex Pro Human Chemokine panel 40-plex)  per lo studio 
di 40 citochine/chemochine e uno studio di analisi di gene expression. 
Risultati. L’analisi proteica del liquor nella prima coorte ha evidenziato la 
presenza di elevati valori di CXCL13 (p=0,00006), CCL19 (p=0,0019), CCL1 
(p=0,00018), e CCL22 (0.0009) rispetto alla popolazione di controllo. L’analisi 
proteica della seconda coorte ha evidenziato, sempre rispetto alla popolazione di 
controllo, un aumento delle seguenti citochine:  CXCL13, CXCL10, CXCL11 e CCL2. 
Dopo stratificazione in base al carico corticale abbiamo evidenziato nei pazienti 
con un maggior coinvolgimento della sostanza grigia un aumento dei livelli 
proteici di CXCL13 e una maggior espressione di CD20, CD138, CXCL13 and LTa a 
supporto di un ruolo della risposta infiammatoria mediata dai linfociti B. 
Conclusioni. L’analisi combinata di liquor e risonanza magnetica suggerisce che la 
risposta immunologica mediata dai linfociti B giochi un ruolo importante nella 
patogenesi della sclerosi multipla e che il livello di infiammazione intratecale ben 
correla con la patologia corticale. I risultati del nostro studio suggeriscono  quindi 
che l’uso di biomarker liquorali potrebbe essere  di supporto nella 
caratterizzazione della patologia corticale nella sclerosi multipla.  
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1. Introduction 
The first description of multiple sclerosis (MS) dates back in the 14th century, but 
only in the 19th century MS became a distinct disease entity when Jean-Marin 
Charcot defined the first correlation between the clinical feature of MS 
(described as “la sclérose en plaques”) and the pathological changes seen in 
post-mortem (Compston et al., 1998). Currently MS is recognized as a chronic 
immune-mediated inflammatory and neurodegenerative disease of the central 
nervous system (CNS), and epidemiologic studies support both genetic and 
environmental components of susceptibility. The pathologic hallmark of chronic 
MS is inflammation both in the white matter (WM) and in the grey matter (GM), 
demyelination with partial restoration of myelin, axonal and neuronal damage, 
and glial scarring (Noseworthy et al., 2000, Lassmann, 2013). 
 
1.1. Epidemiology 
MS is the most common chronic inflammatory disease of the CNS and affects 
more than 2.3 milion people worldwide (Pathwardhan et al., 2005) with a 
prevalence that varies, from high levels in North America and North Europe 
(>30/100.000 inhabitants) to low rates in Sud America and Eastern Asia 
(2/100.000) (Marrie RA et al., 2004).  The current prevalence of MS in Italy is 
estimated at 100-120/100.000 inhabitants; in the province of Padova the overall 
prevalence on 31 December 2009 was 139.8/100.000 inhabitants with an 
increased incidence rate in the last 10 years (5.5/100.00/year); other recent 
epidemiologic studies observed an increase of incidence in Sardinia and in the 
Repubblica of San Marino, suggesting changes in environmental factors more 
than a simply change in ascertainment (Ranzato et al., 2003, Granieri et al., 2008, 
Cocco et al., 2011, Puthenparampil et al., 2013). 
Most people are diagnosed between the ages of 20 and 45 with a gender ratio 
(women/men) from 2/1 to 3/1 in Nordic Countries  (Kingwell et al., 2013, Alonso 
et al., 2008). Previous infection with Epstein-Barr virus, smoking behaviour and 
vitamin D insufficiency are potential susceptibility factors for multiple sclerosis 
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(Marrie RA et al., 2004; Kantarci et al., 2006; Ascherio  et al., 2007 a, b). Although 
MS is not an inherited disease, it is characterized by a strong genetic component  
(Di Santo et al., 2014). Indeed, the risk of developing this condition in biological 
relatives of MS patients increases with increasing degree of kinship (Willer et al., 
2003; Kantarci et al., 2008); farther, linkage analysis studies have revealed 
several gene loci as risk factors including a strong association between HLA-
DRB1*15:01 and MS (Hafler et al., 2007; Jersild C et al., 1973). 
MS is the most disabling neurological disorder of the young adults with 
remarkable sanitary and social costs (Pathwardhan et al., 2005). The average 
annual cost of a MS patient in Italy is about € 39.000, 34.3% of which is 
represented by direct and 65.7% by indirect costs.  
 
1.2. Subtypes of MS 
Heterogeneity and variability characterize MS whose course may be considered 
as the expression of two main clinical manifestation (Confavreux et al., 2006): 
- Relapse of acute neurological symptoms, that last over 24 h suggesting 
structural damage of the brain (D.H. Miller et al., 2012), and that end with 
a complete or partial recovery. It characterizes about 85% of MS disease 
onset.  
- Progression which refers to irreversible accumulation of disability over 
more than six months. 
In 1996 the US National Multiple Sclerosis Society (NMSS) proposed standardized 
definitions for the most common clinical courses of patients with MS, essential 
for mutual understanding between clinicians and investigators and for design of, 
and recruitment for, clinical trials (Lublin et al., 1996). They defined four main 
subtypes: relapsing-remitting, primary progressive, secondary progressive, and 
progressive relapsing MS. 
Relapsing remitting (RR) MS: characterized by clearly defined attack  with full 
recovery or with sequelae and residual deficit upon recovery; periods between 
disease relapses are characterized by a lack of disease progression  
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Secondary progressive (SP) MS: begins with an initial RR course, followed, in 10-
15 years, by progression of variable rate that may also include occasional 
relapses and minor remissions. This subtype represents 40-50% of RRMS cases 
and 60-70% of MS cases. It is a dramatic event in the lifetime of MS patient 
because from this moment on prognosis is compromised and therapy is no 
longer effective. Indeed, once the clinical threshold of irreversible disability 
(score  4 on the Kurtzke Disability Status Scale (EDSS)(Kurtzke et al., 1983)) has 
been reached, disability proceeds irreversibly and independently (Confavreux et 
al., 2003 and 2006). 
Primary-progressive (PP) MS (10-15% of MS cases): disease showing progression 
of disability from onset without plateaus or remission or with occasional plateaus 
and temporary minor improvements. 
Relapsing-progressive (RP) MS: although this has been one of the most 
commonly used terms to describe an important clinical form of MS characterized 
by a combination of relapse and progression, there was no consensus for a 
definition. 
In this light, disability accumulation manifests as an expression of degenerative 
processes that progress independently from inflammatory events.  
Because imaging and biological correlates were lacking in previous phenotypes 
description, in 2013 Lublin and Colleagues ( Lublin et al., 2014) re-evaluated 
definitions of clinical MS phenotypes originally described in 1996. They proposed 
the inclusion of two modifiers to the basic clinical courses of “relapsing” and 
“progressive” MS, namely, disease activity (clinical and radiological) and clinical 
progression in order to improve prognostication and treatment selection (Figure 
1 and 2) (Lublin et al., 2014, Lassmann, 2013). Moreover they introduce new 
subtypes: 
Clinically isolated syndrome (CIS): the first episode suggestive of MS without 
radiological DIS (can be a single or multiple demyelinating lesion) could be 
classified as CIS (Lublin et al., 2014).  The symptoms should last for at least 24 h 
(isolated in time but not necessarily in space). Remarkably the course of MS after 
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CIS is variable: after 15–20 years, a third of patients have a benign course with 
minimal or no disability and a half will have developed secondary progressive MS 
with increasing disability  (D.H. Miller et al 2012) while disease-modifying 
treatments delay the development from CIS to MS (Kennedy et al., 2013). 
Radiological isolated syndrome (RIS): the evidence of a demyelinating process 
identified by MRI in absence of clinical relapses  or neurological symptoms and 
clinical signs (Okuda DT et al., 2009). RIS may raise likelihood of an eventual MS 
diagnosis (Okuda DT et al., 2011), depending on the morphology and location of 
detected MRI lesions (gadolinium-enhancing lesions asymptomatic spinal cord 
lesions) or positive CSF findings. 
 
 
Figure 1. The 1996 vs 2013 multiple sclerosis phenotype descriptions for relapsing 
disease *Activity determined by clinical relapses and/or MRI activity (contrast-enhancing 
lesions; new or unequivocally enlarging T2 lesions assessed at least annually); if 
assessments are not available, activity is “indeterminate.” **CIS, if subsequently 
clinically active and fulfilling current multiple sclerosis (MS) diagnostic criteria, becomes 
relapsing-remitting MS (RRMS). (Lublin et al., Neurology 2014) 
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Figure 2. The 1996 vs 2013 multiple sclerosis phenotype descriptions for progressive 
disease. *Activity determined by clinical relapses assessed at least annually and/or MRI 
activity (contrast-enhancing lesions; new and unequivocally enlarging T2 lesions). 
**Progression measured by clinical evaluation, assessed at least annually. If assessments 
are not available, activity and progression are “indeterminate.” MS = multiple sclerosis; 
PP = primary progressive; PR = progressive relapsing; SP = secondary progressive. (Lublin 
et al., Neurology 2014) 
 
1.3. Diagnostic criteria 
Albeit in the last twenty years the diagnostic criteria for MS have evolved 
significantly, at present there is no single diagnostic test. Thus, diagnosis, 
essentially a clinical diagnosis, is based on a detailed history, careful neurologic 
examination, and supportive paraclinical investigations, including MR (MRI) 
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imaging scans, cerebrospinal fluid (CSF) analysis, evoked potentials, and blood 
tests to exclude confounding diagnoses.  
As the etiology of MS remains unknown and clinical manifestations result from 
involvement of multiple systems (motor, sensory, visual, etc.) in different period 
of time, the diagnosis of MS relies on the acquisition of three basic concepts: 
- No better explanation: to rule out other neurological disorder that can 
mimics MS at onset (Table 1); 
- Presence of dissemination in space (DIS): involvement of different region 
of the CNS demonstrated with the neurological examination or laboratory 
test (MRI, or evoked potential); 
- Presence of dissemination in time (DIT): evidence at different time points 
of temporal evolution of the disease, demonstrated by a new clinical 
attack, by the appearance of new inflammatory lesions at MRI scan, or by 
continued progression for one year. 
 
 
The first diagnostic criteria, developed by Schumacher in 1956, were based 
largely on the results of clinical examination (Schumacher et al., 1965).  Later on 
in 1983, Poser and colleagues created new diagnostic criteria for clinical trials 
and these were supported by laboratory test (evoked potentials, CSF 
Differential diagnosis group Diseases 
Radiological 
Tumor (glioma, isolated CNS lymphoma, 
tumefactive MS 
ADEM 
Balo’concentric sclerosis 
Clinical 
neuroboreliosis 
myelopathy 
vasculitis 
sarcoidosis 
syphilis 
neurocysticercosis 
Behcet's disease 
Table 1. Differential diagnosis of MS 
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examination, and MRI scan)(Poser et al., 1983). Although they have only a 
supportive role, the CSF study permitted the calculation of the IgG index (Link et 
al., 1977) and to reveal the presence of oligoclonal bands (OCBs), which 
represent the best evidence of the intrathecal inflammation characterizing MS 
from the other inflammatory neurodegenerative diseases. 
In addition, the application of MRI in MS led to an increase awareness in the 
number of patient with white matter pathology despite lack of standard 
procedures (Barkhof et al., 1992). 
Only in 1997-2000 Barkhof-Tintorè (Barkhof et al., 1997, Tintoré et al., 2000) 
defined radiological diagnostic criteria for MS; these were included in the new 
diagnostic criteria proposed in 2001 by the International Panel on MS Diagnosis 
chaired by Ian McDonald (McDonald et al., 2001). Thanks to high specificity and 
sensibility, MRI criteria became an alternative to clinical assessment in defining 
dissemination in time and space of MS. To achieve DIS criteria with MRI three 
out of four following conditions had to be fulfilled: a) at least one gadolinium-
enhancing (Gd+) lesion must be present or at least 9 T2 hiperintensive lesions 
must be present if gadolinium-enhancing lesions are absent; b) at least one 
infratentorial lesion must be present; c) at least 1 subcortical lesion must be 
present; d) at least 3 periventricular lesions must be present; only one spinal 
cord lesion could substitute for one brain lesion.  DIS was also proven in the 
presence of two lesions suggestive of MS in conjunction with the presence of 
OCBs. On the other hand, DIT could be established by the presence of at last one 
Gd+ lesion (not the one responsible for the clinical symptoms) in the brain in the 
MRI scan performed at least 3 months after the onset of first clinical symptoms, 
or by the presence of a new T2 hiperintensive lesion or a gadolinium-enhancing 
lesion in the second MRI scan performed not sooner than 3 months after the 
first. Besides, the diagnosis could still be achieved after a second relapse. 
The revision of McDonald criteria in 2005 by Polman and colleagues reduced the 
time needed to prove a radiological DIT (presence of a new T2 hiperintensive 
lesion in the next MRI scan if the previous one was done at least 30 days after 
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the onset of first clinical symptoms, and not sooner than 3 months as previously 
described) (Polman et al., 2005). Furthermore any number of cord lesions can 
substitute for brain lesions and a cord lesion is also assigned the same status as 
an infratentorial lesion (Bot JC et al., 2004).  
In 2010, the McDonald criteria (summary in Table 2) were modified to speed up 
the diagnosis process (Polman et al., 2011). Based on the studies conducted by 
the MAGNIMS (European Magnetic Imaging in MS) group, the criteria for 
radiological DIS were changed and stated that at least one lesion typical for MS 
lesion in at least two out of four locations typical for MS (periventricular, 
subcortical, infratentorial, and in the spinal cord) should be present in the MRI. 
If, at the time of the MRI scan, the patient had clinical symptoms indicating the 
involvement of one of the CNS lesions, this lesion should not be counted. To 
prove DIT MRI scan may be performed earlier (without specifying a time frame)  
and the coexistence of gadolinium-enhancing and non-enhancing lesions was 
considered sufficient. CSF testing was removed from diagnostic criteria. However 
because its important role in the differential diagnosis of MS and in diagnosing 
the primary progressive form of MS, it should be still performed. 
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Table 2. The 2010 McDonald Criteria for Diagnosis of MS (McDonald et al., 2010)
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1.4. Multiple sclerosis lesions and inflammatory response 
In MS, immune dysregulation, possibly triggered by genetic and environmental 
factors, may promote an inflammatory response against self-antigens in the CNS 
which causes inflammation in the brain and spinal cord and results in myelin 
disruption, axonal damage, neuronal loss, glia alterations (Sospedra et al., 2005) 
and release of new potential CNS autoantigens  (as the αβ-cristallin, Bsibsi et al., 
2014).  
Demyelination is characterized by oligodendrocyte loss and could be followed by 
a variable degree of re-myelination. Axonal loss and gliosis are characterized by 
astrocyte proliferation, microglia/macrophage activation and glial fiber 
production occurring in combination with axonal/neuronal damage. 
Pathological hallmark of MS is the presence in the CNS of widespread focal 
inflammatory demyelinating lesions which are characterized, in particular in the 
WM, by infiltrates composed, mostly, by activated T-lymphocytes with a 
dominance of MHC-I restricted CD8+ T cells (Babbe et al., 2000); infiltrating 
macrophages, dendritic cells, B cells and plasma cells are also present (Frischer et 
al., 2009); thus, this coexistence entails potential roles for both cellular and 
humoral immune response. Furthermore, there is an up-regulation of major 
histocompatibility complex class I (MHC-I) molecule expression on inflammatory 
cells, glial cells and neurons depending upon the severity of the disease and the 
activity of the lesions  (Hoftberger et al., 2004). CD8+ T cells are believed to 
induce axonal pathology by direct injury to MHC-I antigen expressing cells such 
as neurons and oligodendrocytes (Batoulis et al., 2010). 
Major histocompatibility complex class II (MHC-II) molecules in the brain are 
mainly expressed on microglia and macrophage. 
In this context pro-inflammatory mediators, such as chemokines and cytokines, 
are also up-regulated (Holman et al., 2011) and amplify the immune response 
through recruitment/activation of naïve resident microglia which cooperate in 
mediating demyelination and neurodegeneration. 
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In the early stages the acute pathological changes affect mainly myelin sheaths 
and oligodendrocytes, however concomitant axon injury is already present and 
frequent in MS, even in normal appearing brain tissue (Dutta and Trapp, 2007). 
MRI studies show how Gd+ T2WM lesions are frequent since early phase 
(suggesting inflammation with blood brain barrier leakage), and how they 
become rare, when patients have entered the progressive phase, suggesting that 
the inflammatory process becomes at least in part trapped within the CNS 
compartment. From a clinical point of view the early phase of the disease is 
characterized by episodes of neurological dysfunction while the subsequent 
progressive phase is characterized by accumulation of disability related to 
pathological changes which are dominated by diffuse inflammation and 
extensive neurodegeneration throughout the whole brain  (Kutzelnigg et al. 
2005).  
Clinical course, age and disease duration influence the dynamic nature of white 
matter MS pathology. Despite active MS plaques predominate in acute and early 
RRMS they are also present with a lesser degree, in the progressive MS phase 
and are characterized by smoldering plaques and microglial activation (Frisher et 
al., 2015).  
Four different patterns of pathology with resulting demyelination have been also 
described in MS lesions (Lucchinetti et al., 2000):  
Type 1 (19%): T cell-mediated where demyelination is macrophage-mediated or 
indirectly by macrophage toxins;  
Type II (53%, the most common observed): lesions are both T cell and antibody 
mediated. This pattern results in demyelination via specific antibodies and 
complement; 
Type III (26% of lesions): results from distal oligodendropathy; degenerative 
changes in distal processes occur and are followed by apoptosis; 
Type IV (2% of lesions): related to primary (non apoptotic death) oligodendrocyte 
damage followed by secondary demyelination (pattern observed in a small 
subset of PPMS patients).  
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1.5. Axonal and neuronal damage in multiple sclerosis  
Axon damage, a key feature of MS pathology, is an early and persistent event in 
MS and has a major impact on permanent neurologic deficit. It is characterized 
by axon swelling, axon transection, Wallerian degeneration and subsequent 
neurodegeneration (Dutta and Trapp, 2007). Axon damage is associated with 
inflammation, especially macrophage infiltration (Pascual et al., 2007). In post-
mortem studies, axon loss has been identified also in the normal-appearing WM 
(NAWM) and cortical GM revealing a more diffuse pathology. Histopathological 
studies have reported the presence of discontinuous staining of axon 
neurofilaments in the NAWM of MS brains and the presence of terminal axonal 
ovoids, suggestive of transection, surrounded by macrophages and activated 
microglia (Trapp et al., 1998). 
Inflammatory activity in MS lesion has been therefore proposed as possible 
immune-mediated mechanism for axon transection and damage (Ferguson et al., 
1997). It has been also demonstrated that activated CD4+ and CD8+ T-cell 
subsets are equally neurotoxic (Giuliani et al., 2003) inducing the release, by 
microglia cell, of free oxygen radicals and nitric oxide (NO) which cause 
mitochondrial injury. CD8+ T-cell are described as possible mediators of axon 
transection lesions (Babbe et al., 2000) by producing direct cytotoxic factors. 
Finally some studies indicate that inflammation induces aberrant glutamate 
homeostasis and production of nitric oxide (NO), which may cause axon damage 
in MS (Werner et al., 2001; Smith and Lassmann, 2002). 
In the clinical setting MRI atrophy represents a reliable hallmark of 
neurodegeneration, and well correlates with progression of disability (Zivadinov 
et al., 2002). Moreover, recent investigations demonstrated that high levels of 
neurofilaments in CSF of MS patients strongly correlated with clinical disability 
suggesting that this molecules could be a good indirect indicator of axonal 
damage (Licke et., 1998). 
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1.6. Grey matter pathology 
MS has been traditionally considered a disease of the WM of the CNS 
characterized by multifocal inflammatory lesions. However in the last 15 years it 
has become increasingly accepted, thanks to neuropathological and 
neuroimaging studies, that cerebral grey matter (GM) damage in MS is evident 
since early MS stages (De Stefano et al.,2003; Chard et al., 2009; Lucchinetti et 
al., 2011) and provides the best correlate of the rate of clinical progression 
(Reynolds et al., 2011; Calabrese et al., 2013) .  
Grey matter damage is characterized by an extensive involvement of cortical and 
deep grey matter (GM) in terms of focal demyelinating lesions, “diffuse” tissue 
abnormalities and irreversible tissue loss (i.e., atrophy).  
 
1.7. Grey matter lesions 
Despite early reports, GM involvement has only recently received attention 
because of its substantial contribution to clinical disability from early disease 
stage. However, already in 1962, Brownell and Hughes reported that 26% of the 
MS lesion affected GM in or around the cortical and subcortical GM  (Brownell 
and Hughes, 1962).  Remarkable, Gilmore and coll. showed recently that the 
affected GM was larger than that of the WM, in particular in the spinal cord and 
cerebellum (Gilmore et al., 2009). 
 
1.7.1. Classification of cortical lesions 
Based on immunohistochemical detection of myelin (Peterson et al., 2001), three 
distinct lesion types have been described within the cortex. This classification, 
currently widely used, identified:  
- type 1 lesions extend across both WM and GM and are often called 
leucocortical lesions (Figure 3.A). These lesions do not extend to the 
surface of the brain.  
- type 2 lesions are contained within the cerebral cortex grey matter and 
often occur around a blood vessel (Figure 3.B)  
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- type 3 lesions are subpial and affect the largest cortical area (Figure 3.C) 
In particular type 3 lesions are the most represented, up to 67% of the cortical 
demyelinated area (Bo et al., 2003; Magliozzi et al., 2007) and are often affecting 
several adjacent gyri. Other type 3 lesions were wedge-shaped with the base at 
the surface of the brain. 
 
Figure 3. Cortical lesion classification. The three types of cortical lesions described by 
Peterson and colleagues are shown: 1.A type I (leukocortical) developing between WM 
and GM; 1.B type II (purely intracortical); 1.C type III (subpial) expanding from the pia 
mater to the internal cortical layers (Adapted from Dutta and Trapp, 2007). 
 
Also at early stages of the disease, the 37% of biopsy samples from MS patients 
revealed a clear evidence of cortical demyelination largely characterized by CL 
type 3.  
 
1.7.2. Grey matter immunopathology 
GM lesions are characterized by a lack of substantial inflammatory infiltrates, 
complement deposition and blood brain barrier damage; this aspect led to the 
suggestion that the mechanisms underlying GM and WM pathology differ 
substantially (Bo et al., 2003; Brink et al., 2005; Van Horssen et al., 2007) and 
that activated microglia are the dominant effector cell population causing GM 
damage (Peterson et al., 2001; Vercellino et al., 2007).  
Despite reduced cortical inflammation, the cortical GM seems to be affected also 
by myelinotoxic molecules that circulate within the Virchow Robin space 
resulting in perivenular demyelination, and within the CSF determining subpial 
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and periventricular demyelination (Ransohoff et al., 2003). In the last decade, 
several post-mortem studies have revealed that the extent of meningeal 
inflammation associates positively with subpial cortical demyelination, 
suggesting that chronic immune activity in the subarachnoid compartment plays 
a key role in mediating damage in the adjacent cortical GM (Magliozzi et al., 
Brain 2007; Howell et al., 2011; Choi et al., 2012; Lucchinetti et al., 2011). Factors 
released by immune cells circulating in the CSF and/or colonizing the 
subarachnoid space may diffuse across the pial membrane, inducing a gradient 
of glia and neuronal pathological alterations, directly and/or indirectly by 
activating microglia (Magliozzi et al., 2010). The role of meningeal inflammation 
in cortical pathology is evident since the early phase of the disease (Lucchinetti 
et al., 2011; Calabrese et al., 2015; Gardener et al., 2013). Noteworthy, in the 
same study, Lucchinetti and coll. observed that active cortical demyelination and 
inflammation is frequent in early RR phase. 
Besides, deep grey matter is different affected, suggesting that grey matter 
pathology  in MS appears to be regionally variable and reflecting the indirect role 
of specific cells (i.e. interneurons). 
 
1.7.3. Neuronal damage in cortical lesions 
Histopathological studies support the hypothesis that neuron injury occurs in 
cortical lesion and is characterized by neurofilament protein positive swellings 
and consequent disruption of normal cellular transport, and by neurite 
transection emphasized by terminal end bulbs (Peterson et al., 2001). The 
correlation between neuritic transection and microglia activation suggests that 
dendrites and demyelinated axons are vulnerable and strictly associated to 
microglial activation in cortical lesions (Trapp et al., 1998; Dutta and Trapp, 
2007).  
In healthy conditions microglia are the resident immune cells of the CNS, exist in 
resting state and provide surveillance of the cerebral microenvironment. Thanks 
to their versatile functional state, microglia are involved in phagocytosis of 
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apoptotic cells, antigen presentation (APC), production of different types of free 
radicals, expression of cytokines and chemokines, and production of growth 
factors and prostanoids (Aloisi, 2001; Mittelbronn et al., 2001). Microglia 
contribute to neuroprotection and neurodegeneration through release of anti-
inflammatory and pro-inflammatory molecules.  
Besides, pro-inflammatory and cytotoxic molecules as well as cell contact-
dependent mechanisms of T cell-mediated damage, may lead to microglia and/or 
macrophage activation and oligodendrocyte injury (Calabrese et al., 2015). 
Moreover microglia seems to play an important role because it is correlated with 
focal loss of the glutamate transporters (EAAT1 and EAAT2); indeed alteration of 
glutamate reuptake found in MS cortical lesion in the presence of activated 
microglia could be associated with signs of neuronal and synaptic damage 
suggestive of excitotoxicity (Vercellino et al., 2007).  
In addition to their role in immune surveillance and phagocytosis, activated 
microglia can play a neuroprotective role and enhance nerve repair by physically 
removing synaptic input with a process, known as “synaptic stripping” (Graeber 
et al., 1993) which promotes survival of neurons (Hardingham and Bading, 2003). 
 
1.7.4. Cortical lesions and physical and cognitive impairment in MS 
Cognitive functions are affected in approximately 45-65% of MS patients (Rao et 
al., 1995). MRI studies have described a significantly greater cortical/subcortical 
disease burden in patients with cognitive impairment (Rovaris et al.,2000). Even 
at the early disease stages, they confirmed the major role of cortical damage in 
determining cognitive disability; in this case GM is characterized by more 
extensive cortical volume loss in frontal temporal and parietal regions (Amato et 
al. 2007). Noteworthy cortical lesions seen in early MS are usually highly 
inflammatory and correlate with cognitive impairment (Geurts and Barkhof 2008; 
Lucchinetti et al., 2011). 
Besides, the use of myelin immunohistochemistry and new MRI acquisition 
methods have permitted to better quantify the real extent of GM damage and to 
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reveal the relationship, present from the clinical onset, between GM pathology 
and physical disability and cognitive dysfunction more convincingly than WM 
damage (Pirko et al., 2007; Popescu et al., 2012; Lucchinetti et al., 2011; Geurts 
JJG et al. 2012). In a MRI study, Calabrese and coll. detected CLs, by Double 
Inversion Recovery (DIR), in the majority (64%) of RRMS and (73%) SPMS patients 
and observed that patients with higher CLs showed a higher Expanded Disease 
Status Scale (EDSS) score (Calabrese et al., 2007). Also MRI longitudinal studies 
revealed how patients with higher increase in CLs number showed a clinical 
worsening at follow-up (Calabrese et al., 2010; Roosendal et al., 2009).  
Remarkably, the presence of CLs is associated with higher level of intrathecal 
synthesis of Ig (IgG and IgM), and this association correlates with highest risk of 
worse clinical evolution after three years (Calabrese et al. 2012). 
 
1.8. Diffuse cortical pathology 
Several neuropathological studies revealed an extensive and irreversible 
“neurodegenerative” process involving grey matter (Pirko et al., 2007; Howell et 
al 2011) characterized by GM demyelination and neuronal damage/loss which 
impair cortical function (Peterson et al., 2001). GM involvement differs 
accordingly to different disease stages. Wegner and coll. reported that also in the 
normal appearing cortex a diffuse reduction of cortical thickness by 10% 
(Wegner et al. 2006), and significant neocortical and glial degeneration.  
In-vivo grey matter atrophy measures reflect combinations of demyelination, 
neurite transection (Peterson et al., 2001) and reduced synapse or neocortical 
and glial densities (Dutta et al., 2011; Wegner et al. 2006). Mitochondrial 
dysfunction has been proposed as one of the main mechanisms of diffuse injury, 
as the result of mitochondrial DNA deletions, induced by inflammation, in 
neurons located in layer VI and immediate subcortical white matter (WM) 
irrespective of lesions (Campbell et al., 2011). Currently, modern neuroimaging 
techniques and available software have been used to correlate measure of GM 
atrophy with clinical disability and cognitive impairment (Geurts  et al., 2012 )  
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Finally, the appearance of new CLs in the early phase of the diseases is one of the 
best correlate of the reduction of the cortical thickness (Cth), a measure of 
atrophy, suggesting that, at least at the beginning of the disease, the early focal 
cortical pathology plays a relevant role in the development of brain atrophy 
(Calabrese et al., 2015) 
 
1.9.Grey matter pathology and MRI 
The improvement of MRI technology, having higher sensitivity for the GM, has 
allowed, in the last 10-15 years, to better describe GM pathology in vivo from the 
early disease phase even before the appearance of WM lesions.  
Numerous studies and new advanced non-conventional MRI techniques have 
improved the detection methods for CLs, in particular Double Inversion Recovery 
(DIR) improves the sensitivity of the detection of CLs (Geurts et al., 2005; 
Pouwels et al., 2006), in particular with 3 Tesla MR  (Simon et al., 2010). 
Calabrese and coll. revealed in a longitudinal study of three years how an 
accumulation of CLs number detected with DIR correlate with disability 
progression (Calabrese et al., 2010).  
However DIR sequences showed low sensitivity in detecting CLs, as comparative 
histopathological studies have demonstrated that low sensitivity depends only 
on the size of CLs (Seewann et al., 2011). An important improvement has been 
recently achieved combining DIR sequence with phase sensitive inversion 
recovery PSIR (Favaretto et al. , 2015).  The authors describe the high ability of 
PSIR in disclosing and classifying CL, in particular the presence of CLs in CIS 
patients further pointed out the relevance of cortical pathology in MS 
Besides, the availability of not-conventional MRI sequences permitted to detect, 
also in the early phase, cortical metabolite changes (reduced levels of N-acetyl 
aspartate) (Kapeller et al., 2001; Tiberio et al., 2006; Chard DT et al., 2002) and 
atrophy (Audoin B et al., 2006). Magnetization transfer allowed the detection of 
cortical abnormalities (severe axonal loss and swelling) that were related to the 
disability of MS patients (Fisniku et al., 2009; Fisher et al., 2007). 
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Noteworthy, dedicated software (as the Freesurfer software, 
http://surfer.nmr.mgh.harvard.edu/, or SIENAX or FSL) applied on High 
Resolution MRI images, allowed the assessment of global and regional GM 
atrophy in RRMS and SPMS patients (Davies et al., 2004, Sastre-Garriga et al., 
2005). In 2003, Sailer and coll. demonstrated by means of Freesurfer, that a 
cortical thinning is present in the frontal and temporal lobes of MS patients 
(Sailer et al., 2003). Soon after, two separate studies described that the rate of 
atrophy progression was already present in the early phase of MS (De Stefano et 
al., 2003; Chard et., al 2004) suggesting once again that the neurodegeneration is 
a process that initiate at the disease onset.  
Calabrese and coll. confirmed in a cohort of 115 MS patients that the real extend 
of GM atrophy  (Calabrese et al., 2007) involves more cortical areas and is 
already present in the early MS.  
It seems that diffuse GM atrophy is only partially related to the white matter 
damage visible by MRI (Chard et al., 2002) and the correlation between GM 
volume and white matter damage, revealed by diffusion tensor imaging (DTI), 
appears only moderate (Sbardella et al., 2013).   
Finally regional analysis of GM atrophy and GM lesion maps permitted to detect 
specific imaging distribution both of CL distribution and regional thinning 
(Calabrese et al., 2010), however the correlation between focal and diffuse 
damage seems to be only moderate and more evident in the early phase of the 
disease (Calabrese et al., 2015). 
All these studies suggest that in MS grey matter pathology may be a major 
determinant of longer-term outcomes in MS and that all together not-
conventional MRI sequences represent an additional useful paraclinical tool to 
monitor MS evolution and for a better stratification of the patients for inclusion 
in clinical studies. 
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1.10. Meningeal inflammation and B-cell response in MS 
A growing number of neuropathological studies (Prineas et al., 1979, Serafini et 
al, 2004; Magliozzi et al, 2007; Frischer et al., 2009) have emphasized the 
contribution of inflammatory process occurring in the meningeal compartment 
of MS patients to cortical pathology, also at early disease stages (Lucchinetti et 
al., 2011). Indeed, they revealed that the extent of meningeal inflammation 
associates positively with subpial cortical demyelination and disease progression 
(Magliozzi et al., 2007; Howell et al., 2011; Choi et al., 2012). 
Magliozzi and coll. have shown the presence of abundant meningeal 
inflammation with the formation of ectopic follicle-like structures, also named 
tertiary lymphoid organs (TLO) in a substantial proportion of secondary 
progressive MS (SPMS) cases (Serafini et al., 2004; Magliozzi et al., 2007) 
associated with the more severe clinical features. These structures are formed by 
infiltrating B-cells, T-cells, dendritic cells and plasma cells, which become 
organized anatomically and functionally as in secondary lymphoid organs (SLO), 
leading to de novo formation of tertiary lymphoid organs (TLO). TLO have been 
previously found also in other autoimmune disorders, such as rheumatoid 
arthritis, lupus erythematosus systemic, suggesting that they can represent 
niches of chronic inflammation persisting in the target organs (Aloisi and Pujol-
Borell, 2006).  
In MS the presence of lymphoid follicle-like structures containing B cells and a 
reticulum of CXCL13+ and FDC-M1+ follicular dendritic cells within the meninges 
suggest that under chronic inflammatory conditions, the meningeal 
compartment is the site where ectopic lymphoid follicles preferentially. Such 
abnormal formations may contribute to pathogenic process through local 
amplification of autoimmune response which results compartmentalized in CNS 
and therefore chronic immune activity perpetuated within the subarachnoid 
compartment may play a key role in mediating damage in the adjacent cerebral 
cortex of SP and PPMS affected patients. 
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In particular, it may be suggested that the local persistence of inflammatory cells, 
such as B- and T-lymphocytes and macrophages, could be responsible for the 
release of inflammatory mediators (cytokines and chemokines) and proteolytic 
enzymes that can accumulate in the subarachnoid space and diffuse via CSF 
circulation. These inflammatory mediators can easily cross the pial surface and 
mediate directly the tissue damage of the bathed cortical GM, or indirectly by 
activation/alteration of the cortical microglia and astrocyte population 
(Calabrese et al., 2015). This is supported by the observation that high level of 
meningeal inflammation and cortical pathology is accompanied by increased 
gene expression of inflammatory cytokines, such as Tumor Necrosis Factor (TNF) 
and Interferon gamma (IFNg), in the meninges of post-mortem SPMS cases and 
elevated levels of the same proteins in the corresponding CSF (Gardner et al., 
2013), compared to healthy controls. 
Sellebjerg and coll. have also described an increased concentration in vivo of 
CXCL13 (a B-cell chemokine), which supports a role for the recruitment of B cells 
(Sellebjerg et al., 2009).  
Molecular analysis of B-cells and plasma cells isolated from CNS lesions revealed 
that the observed intrathecal humoral response is antigen-driven and B-cell 
clonotypes persist over time in CNS compartment (Baranzini et al., 1999; 
Colombo et al., 2000; Owens et al., 2003;  Colombo et al., 2003). However it has 
been not yet elucidated if antibodies, even if present from early stages (Genain 
et al., 1999), are only an epiphenomenon of tissue damage (Sospedra and 
Martin, 2005; Owens et al., 2006, Hauser, 2015). Neuropathology studies 
indicate that antibody-mediated demyelination is one of the predominant 
pathogenetic mechanisms involved in white matter lesion formation in a 
substantial proportion of MS patients (Lucchinetti et al., 2000). 
Noteworthy the presence of elevated CNS levels of immunoglobulins (Ig) and the 
presence of oligoclonal IgG in the cerebrospinal fluid (CSF) are the most 
consistent immunological abnormalities characterizing MS compared to other 
inflammatory neurodegenerative diseases (Petzold et al., 2013). Such intrathecal 
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immunoglobulin synthesis is thought to be sustained by long-lived plasma cells 
recruited to or differentiating within the CNS (Prineas and Wright, 1978). 
 
B-cells play also a role in down-regulating immune reaction and promoting repair 
through the release of neurotrophic factors and pleotropic cytokines (as IL10, 
which seems to have a protective role). Understanding how abnormal regulation 
of the B-cell response contributes to the pathogenesis of MS will be fundamental 
for the identification of specific B-cell therapies, targeting not only the antibody 
production but also the regulatory and antigen presenting activities of B-cells. Up 
to now three therapeutic monoclonal antibodies targeting CD20-positive B cells 
(rituximab, ocrelizumab and ofatumumab) have been investigated providing 
evidence for beneficial effect of B cell depleting therapies in MS. (Hauser et al., 
2008; Sorensen and Blinkenberg, 2016). 
 
1.11. CSF analysis and multiple sclerosis 
CSF recent findings provided evidence for a direct correlation between the 
immune cells present in the CSF and CNS, especially related clonally expanded B 
cells (Lovato et al., 2011), which together with plasmablasts are involved in IgG 
secretion (Obermeier et al., 2011). 
The presence of oligoclonal bands (OCBs) and the increased IgG-index (i.e. >0,7) 
are important hallmark of MS in the CSF of affected patients (Kabatea et al. 
1948) suggesting an intrathecal chronic inflammatory process. However, given a 
low specificity, CSF testing alone has only a supportive role in MS diagnosis; 
recently Lublin and coll. emphasized that currently no biological CSF marker 
reliably differentiates between MS disease subtypes, and they also focalized the 
attention on the need to exploit the potential of CSF biological markers (Lublin et 
al. 2014).   
Moreover, the CSF could provide important issue in order to understand the 
immunopathology of MS; indeed the presence of IgG suggests a humoral 
immunity partially responsible for the development of focal cortical damage 
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observed in GM. Several studies have revealed the association between the 
degree of meningeal inflammation together with the presence of B-cell follicles, 
and the gradient of neuronal and axonal loss (Magliozzi et al., 2010; Gardner et 
al., 2013), suggesting that the humoral cytotoxicity is a potential responsible for 
the cortical demyelination, even before white matter lesions have formed 
(Popescu et al. 2011). 
Recently, the B-cell attracting chemokine C-X-C motif chemokine 13 (CXCL13) 
and the extracellular matrix-degrading enzyme metalloprotease-9 (MMP-9) have 
been proposed as possible specific CSF biomarkers (Stangel et., al 2013) which 
can suggest a possible connection between meningeal inflammation and cortical 
damage (Stangel et., al 2013). Conversely myelin basic protein, neurofilament 
light chain subunit and chitinase-3-like-1 (Teunissen et al., 2012; Modvig et al., 
2015), have been identified as marker of tissue damage and predictor of 
neurological disability. 
Gene-expression studies in the CSF are limited due to the small number of cells 
collected. These studies provided evidence of increased expression of genes 
involved in T-, NK-, and B-cell function in CSF cells (Brynedal et al. 2010; Jernås et 
al., 2013). 
Recent efforts in improving diagnosis and management of MS and providing 
reliable biological markers have been carried out.  Veroni and coll. performed a 
gene expression analyses in paired cerebrospinal fluid (CSF) and peripheral blood 
mononuclear cells (PBMC) from MS patients with a reliable improved sensitivity 
pre-amplification real-time reverse-transcription polymerase chain reaction (RT-
PCR). They identified two factor grouping genes: factor 1 was related to a type-1 
IFN response  cytotoxic/Th1 T-cell activation, and inflammation; factor 2  was 
likely related  to an inhibitory circuit involving immune regulatory cells (CD68, IL-
10, MHC class II, and CD4) (Veroni et al., 2015). 
Komori and coll. identified, supported by machine learning algorithms, that 
soluble CD27 is the best single biomarker of active intrathecal inflammation in 
comparison to IgG Index and OCB and it could be considered as an hallmark of a 
PhD Thesis   PhD Candidate: Dr. Dario Seppi 
 
32 
 
T-cell mediated inflammation (Komori et al., 2015). CD27 molecule is selectively 
higher in the progressive MS subtype indicating that T-cell infiltration of CNS is 
represented in progressive MS, in which it may play a pathogenic role. This is in 
contrast with traditionally and currently accepted notions that inflammation no 
longer play a pathogenic role in chronic forms. 
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2. Hypothesis and aims 
We suggest that the rate at which cortical pathology accumulates and the level 
of intrathecal inflammation, associated to inflammatory activity in the CSF, might 
provide an indication of severity of disease process and might predict/monitor 
the evolution of the disease and an early conversion to the progressive phase of 
the disease.  
Therefore, the characterization of a panel of biomarkers and paraclinical tools 
able to identify those patients having more severe cortical damage might help 
the clinicians in choosing more aggressive therapeutic strategies at the earliest 
phase of the disease when the disease course is still modifiable. 
  
The aim of the study is to combine CSF molecular and protein analyses with 
advanced MRI imaging techniques, able to better identify cortical grey matter 
demyelination, in order to characterize potential early biomarkers of GM 
pathology and disease progression with prognostic and predictive value and to 
obtain information on the biological and immunological mechanism that link the 
inflammatory process of the GM and the progressive neurodegeneration. The 
information obtained from these techniques is also investigated as possible 
indicator of clinical recovery. 
It is therefore that, in this study, we have performed protein analysis and gene 
expression analysis of CSF samples from MS patients, in the very  early phase of 
the disease and therapy naïve, who underwent a complete  diagnostic work 
up comprehensive of non-conventional MRI sequences in  the MS Center in 
Padova. Finally this combined approach may identify patients with a more severe 
prognosis who could benefit from an earlier and more effective long-term 
therapeutic strategy aimed at improving their quality of life and reducing the 
disease-related indirect costs.  
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3. Methods 
 
3.1. Study population 
First MS cohort: Thirty-five patients presenting with symptoms/signs suggestive 
of MS, were recruited between February 2009 and September 2011 at the MS 
Centre in Padova. At the time of CSF sampling none of the patients was treated 
with immunomodulatory or immunosuppressive therapies. Four patients were 
treated with high doses of steroids in the month prior to lumbar puncture. Four 
subjects presenting with symptoms and MRI compatible with a diagnosis of 
cerebrovascular disease and a woman affected by subacute combined sclerosis 
(in remission phase) were recruited as non-inflammatory controls (Table 3). In 
these subjects other neurological (inflammatory and/or degenerative) diseases 
were definitely excluded. The individuals were re-evaluated retrospectively 
according to McDonald Criteria (Polman et al., 2011): 22 were CIS and 13 RRMS 
(at early phase of the disease).  
 
 
Second MS cohort (independent cohort): From January 2014 to May 2015, 31 MS 
patients and 13 controls (other non-inflammatory neurological diseases - ONND), 
at their disease onset and without any therapy, have undergone a complete 
diagnostic work-up, comprehensive of a lumbar puncture and a MRI (the 
Table 3. Demographic and clinical data of the first MS cohort. Data are reported as mean ± 
standard deviation (range). For Expanded Disability Status Scale (EDSS), median and (range) 
are provided.  Abbreviation: y year; m month; DD disease duration; FU follow up; PI 
Progression Index (PI) LP lumbar puncture; CIS clinically isolated syndrome; RRMS relapsing 
remitting multiple sclerosis  
 n. F/M Age 
(y) 
DD (m) EDSS EDSS 2 CIS/ 
RRMS 
DD at 
LP 
FU (m) PI 
MS 
patients 
35 21/1
4 
34.97 
±10.14 
4±2 m 
(0-18) 
1.5±0.5  
(1.0-2.5) 
1.5±0.5 
(1.0-6.5) 
22/13 4±4.5 51.2 
(12-76) 
0.68±0.3 
(-0.92-1.12) 
Control 
subjects 
5 4/1 52±6 N/A N/A  N/A N/A N/A N/A 
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complete MRI protocol was set up in collaboration with the Neuroradiology Unit 
of the University Hospital of Padova); time interval between lumbar puncture 
and MRI was 18.39±10.7 days. According to McDonald Criteria (Polman et al., 
2011), 12 individuals were CIS and 19 were RRMS (at early phase of the disease, 
disease duration less than five years) 
 
 
n. F/M 
Age at LP 
(y) 
DD (m) EDSS 
Radiological/clinical 
disease activity 
CIS/ 
RRMS 
MS 
patients 
31 18/13 36.19±9.54 
17.0±28.3 
(0-61) 
1.52±1.0 
(1.0-3.5) 
11/31 12/19 
Control 
subjects 
13 11/2 42.92±10.31 N/A N/A N/A N/A 
Table 4. Demographic and clinical data of the second MS cohort. Data are reported as mean ± 
standard deviation (range). For Expanded Disability Status Scale (EDSS), median and (range) 
are provided. Abbreviation: y year; m month; LP lumbar puncture; DD disease duration, CIS 
clinically isolated syndrome; RRMS relapsing remitting multiple sclerosis. 
 
 
Clinical evaluation: the degree of neurological disability has been scored using 
the Expanded Disability Status Scale (EDSS).  Clinical and/or radiological disease 
activity was present in 11 out of the examined 31 patients. None of the patient 
was previously treated with immunomodulant or immunosuppressive, while 
administration of high doses of steroids in the month prior to lumbar puncture 
was considered an exclusion criterion. Clinical and demographical data are 
summarized in Table 4. 
The study was approved by the local Ethics Committee (CE per la 
Sperimentazione, Azienda Ospedaliera – Università degli Studi di Padova). All 
patients gave written informed consent 
 
3.2. MRI analysis 
Morphological MRI Image Acquisition (first cohort) 
Brain MRI was performed in all the patients at study entry. Images were acquired 
using a 1.5 T scanner (Achieva, Philips Medical Systems, Best, The Netherlands) 
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with 33 mT/m power gradient and a 16-channel head coil. No major scanner 
hardware upgrades occurred during the study, and bimonthly quality-assurance 
sessions assured measurement stability.  
The following images were acquired for each subject:  
Cerebral and spinal MRI sequences 
 DIR: repetition time (TR)=15,631 ms; echo time (TE)=25 ms; inversion 
time (TI)=3400 ms; delay=325 ms; echo train length (ETL)=17; 50 
contiguous axial slices with thickness=3 mm; matrix size=130 x 256; and 
field of view (FOV)=250 x 200 mm2;  
 Fast fluid attenuated inversion recovery (FLAIR): TR=10,000 ms; TE=120 
ms; TI=2500 ms; ETL=23; 50 contiguous axial slices with thickness=3.0 
mm; matrix size=172 x 288; and FOV=250 x 200 mm2;  
 Three-dimensional (3D) fast field echo (FFE): TR=25 ms; TE=4.6 ms; 120 
contiguous axial slices with the off-centre positioned on zero with 
thickness=1.2 mm; flip angle=30°; matrix size=256 x 256; and FOV=250 x 
250 mm2;  
 Cervical and dorsal cord short time inversion recovery: TR= 2500 msec, 
TE= 60 msec, inversion time= 170 msec; 15 sagittal slices, slice thickness= 
3.5mm, gap= 0 mm, matrix size= 272 x 512, filed of view= 250x250 mm2) 
 
Morphological MRI Image Acquisition (second cohort) 
MRI images have been  be acquired with a 3 Tesla Achieva TX system (Philips 
healthcare, Best, The Netherlands) with a 64-channel coil. No software upgrade 
was performed during the study period and a weekly check scanner ensured the 
stability of the parameters acquired. 
The following set of images has been obtained from each subject:  
Cerebral MRI sequences 
 Three-dimensional T1 turbo field echo (3D T1 TFE): n° slices (sagittal) 180. 
Duration: 5 min. Flip angle 8°. TR 8 msec. TE 4 msec. Thickness: 1 mm. 
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 T1 Inversion Recovery Turbo Spin Echo (T1 IR TSE) with gadolinium (gad): 
n° slices 34. Duration: 3 min. Flip angle 90°. TR 2000 msec. TI 800 msec. 
TE 20 msec. Thickness: 4 mm. 
 T2 Turbo Spin Echo (T2 TSE): n° slices 34. Duration 4 min. Flip angle 90°. 
TR 2700  msec. TE 80 msec. 
 Diffusion Weighted Imaging (DWI): n° slices 52. Duration 1.30 min. Flip 
angle 90°. TR 3700 msec. TE 100 msec. Thickness 4 mm. 
 Apparent diffusion coefficient (ADC): n° slices 26. Duration 1.30 min. Flip 
angle 90°. TR 3700 msec. TE 100 msec. Thickness 4 mm. 
 Three-dimensional Double Inversion Recovery (DIR 3D): n° slices (sagittal) 
300. Duration 7 min. Flip angle 90°. TR 5500 msec. TE 300 msec. TI 2550 
msec. Thickness 1 mm. 
 Three-dimensional Fluid Attenuated Inversion Recovery  (FLAIR 3D): n° 
slices (sagittal) 365. Duration 7 min. Flip angle: 90°. TR 4800 msec. TE 300 
msec. TI 1650 msec. Thickness 1 mm. 
Spinal MRI sequences 
  T1_TSE: n° slices 15 (sagittal), Duration 5 min. Flip angle: 80°. TR 8 msec. 
TE 4 msec. Thiclness: 3 mm. 
 T2_TSE: n° slices 15 (sagittal). Duration 5 min. Flip angle 90°. TR 4000 
msec. TE 100 msec. Thickness 3mm. 
 Short tau inversion recovery (STIR): n° slices 15 (sagittal). Duration 4 min. 
Flip angle 90°. TR 5000 msec. TE 60 msec. TI 210 msec. Thickness 3 mm. 
 MFFE (sagittal): n° slices 15. Duration 4 min. Flip angle 28°. TR 700 msec. 
TE 8 msec. Thickness 3 mm 
 
3.3. MRI image analysis 
Cortical lesions (CL) and white matter (WM) lesions identification (first cohort): 
All images were assessed by two experienced observers who were blinded to the 
patients’ identity. On DIR images, particular attention was devoted to identifying 
artifacts, and CLs were defined as those lesions confined to the cortical ribbon 
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and not involving the underlying subcortical WM (Calabrese et al., 2007). 
However, considering the resolution of DIR images, the possibility that some CLs 
extend into the juxtacortical WM cannot be excluded. 
The number of CLs was assessed on DIR images, and CL volumes were calculated 
using a semiautomatic thresholding technique based on the Fuzzy C-mean 
algorithm, (Pham et al., 1999 and Pham et al., 2000)  included in software 
developed at the National Institutes of Health's Medical Images Processing, 
Analysis, and Visualization (http://mipav.cit.nih.gov). The same procedure was 
applied to FLAIR images, to identify and segment WM lesions, thus obtaining a 
T2 hyperintense WM lesion volume (T2WMLV) (Calabrese et al., 2010). 
The number of Gd-enhancing lesions was determined on post-contrast Gd-
enhanced T1-weighted images. 
 
Global and regional cortical thickness evaluation (first cohort): 
Global and regional cortical thickness (CTh - mean of right and left hemispheres) 
was performed on the volumetric FFE datasets by means of the longitudinal 
stream included in the FreeSurfer image analysis suite (release v5.1.0), available 
online (http://surfer.nmr.mgh.harvard.edu/) (Fischl et al., 2000). All images were 
accurately controlled for errors/artifacts by an experienced neurologist.  
 
Cortical lesions (CL) and white matter (WM) lesions identification (second 
cohort): 
On DIR images, CLs have been defined as those lesions confined to the cortical 
ribbon and not involving the underlying subcortical WM.  
WM and GM lesion volume has been computed respectively on FLAIR and DIR 
images by means of a manual volume of interest (VOI) delineation of 
hyperintense regions. The lesion delineation has been performed by two 
experienced Neurologists, blinded to clinical evaluation, using the MRIcron (v. 
2013) software package. 
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The number of Gd-enhancing lesions was determined on post-contrast Gd-
enhanced T1-weighted images. 
 
 
 
Global and regional cortical thickness evaluation (second cohort): 
Cortical reconstruction and volumetric segmentation has been performed on 
data sets of anatomical 3D-T1 with the Freesurfer image analysis suite (release v. 
5.3), which is documented and freely available for download. To avoid a possible 
bias in image segmentation due to the presence of WM lesions, such lesions 
were aligned to MNI152 standard-space 
(http://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin6) and the T1-
weighted volume (also in MNI152 standard-space) was refilled with values 
randomly extracted from a Gaussian distribution with the same mean and SD of 
normal-appearing tissue using the FSL suite (release v 5.0.6) 
 
3.4. CSF analysis 
First cohort: CSF was collected by non traumatic lumbar puncture between 8.00 
and 9.00 a.m.. Routine examination on paired CSF and serum specimens 
included: cell count and characterization (lymphocytes/monocytes), albumin 
CSF/serum ratio to estimate the integrity of the blood-brain barrier, calculation 
of intrathecal IgG synthesis by means of quantitative formulae (IgG Index, IgG 
HypFunct), and demonstration of IgG oligoclonal bands (OCBs) by 
isoelectricfocusing and specific IgG immunofixation. After immediate 
centrifugation, the CSF cell pellet was separately stored at -80 °C , while the cell-
free CSF supernatant  was aliquoted and stored at -20°C until cytokine 
determination. 
 
Second cohort: As the previous method of collecting and storing the CSF samples 
has shown critical steps to be improved, the methodology for CSF storing and for 
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RNA extraction from the cell fraction has been optimized and applied to the 
second independent cohort. In particular, for each individual the CSF sample 
have been collected by lumbar puncture and, within 30-60 min, centrifuged to 
separate the cellular component from cell-free supernatant. CSF supernatant has 
been stored at -80 °C for protein-array analysis, while the cell pellet has been 
separately stored at -80 °C for RNA extraction and analysis.  
 
3.4.1. Protein analysis 
On the CSF samples (first and second cohort), using the Bio-Plex System (Biorad - 
Bio-Plex Pro Human Chemokine panel 40-plex) in collaboration with Dr. F. 
Facchiano and Dr. S. Rossi at the Department of Hematology of ISS, we 
performed a protein immune-assay  analysis to assess the presence and levels of 
40 inflammatory molecules including the most important cytokines and 
chemokines (Table 5). The Bio-Plex multiplex system, enables the detection and 
quantification of multiple analytes (proteins and peptides, or nucleic acids) in a 
single 50 µL sample volume. In particular, Bio-Plex assays are bead-based assays 
that can be performed in a mixed array (multiplexed) which resembles the  
sandwich analysis technique: capture antibodies direct against the desired 
biomarker are covalently coupled to the beads; coupled beads react with the 
sample containing the biomarker of interest; after a series of washes to remove 
unbound protein, a biotinylated detection antibody is added to create a 
sandwich complex. The final detection complex is formed with the addiction of 
streptavidin-phycoerythrin (SA-PE) conjugate. Phycoerythrin serves as a 
fluorescent indicator, or reporter. The reader, a flow-cytometry based 
instrument (Luminex-based), combines two lasers, fluidics, and real-time digital 
signal processing to distinguish up to 100 different sets of color-coded 
polystyrene beads, each bearing a different assay, allowing therefore both 
qualitative and quantitative analysis of the analytes. Afterwards raw data were 
normalized according to the CSF protein concentration. 
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3.4.2. Gene expression analysis 
Pre-Amplification real time RT-PCR (second cohort) 
Total RNA was extracted from CSF cells (median = 43987,84± 81001,69, range 
1800 406000) using the AMBION RNAqueous micro kit (LifeTechnologies, Grand 
Island, NY), according to the manufacturer’s instructions, including genomic DNA 
digestion. Because of the very low and highly variable RNA yield from CSF cells, 
the entire volume (16 μl) of RNA extracted from each CSF sample was reverse 
transcribed. Reverse-transcription (RT) was performed using the High Capacity 
Reverse Transcription kit with RNase inhibitor (LifeTechnologies). The resulting 
cDNA was diluted to a final volume of 50 µl and splitted into four 12,5 µl aliquots. 
To increase the number of targeted copies, each cDNA aliquot was amplified for 
the specific gene assays by pre-amplification reaction (14 cycles) using the 
TaqMan PreAmp Master Mix (LifeTechnologies) and pooled gene-specific 
primers, at the reaction conditions indicated by manufacturer. Inventoried 
TaqMan gene expression assays were used to study cellular genes, respectively 
(Table 6). Cellular gene assays were pre-amplified together with the selected 
house-keeping gene GAPDH. The pre-amplification product was diluted 1:5 up to 
250 µl in H2O and 4 µl of this dilution were used as template for a single real-
time PCR analysis. Quantitative PCR experiments were performed in triplicate 
with the same inventoried TaqMan assays used in the pre-amplification step (250 
nM probe and 900 nM each primer), using the 7500 Real-Time PCR System 
(LifeTechnologies) for cellular genes. Thermocycling parameters were 50°C (2 
min), 95°C (10 min), followed by 40 cycles of 95°C (15sec), 60°C (1 min) for 
cellular genes. The results of gene expression analysis were obtained as Ct values 
• 6Ckine / CCL21 
• BCA-1 / CXCL13 
• CTACK / CCL27 
• ENA-78 / CXCL5 
• Eotaxin / CCL11 
• Eotaxin-2 / CCL24 
• Eotaxin-3 / CCL26 
• Fractalkine / CX3CL1 
• GCP-2 / CXCL6 
• GM-CSF 
• Gro-α / CXCL1 
• Gro-β / CXCL2 
• I-309 / CCL1 
• IFN-ϒ 
• IL-1β 
• IL-2 
• IL-4 
• IL-6 
• IL-8 / CXCL8 
• IL-10 
• IL-16 
• IP-10 / CXCL10 
• I-TAC / CXCL11 
• MCP-1 / CCL2 
• MCP-2 / CCL8 
• MCP-3 / CCL7 
• MCP-4 / CCL13 
• MDC / CCL22 
• MIF 
• MIG / CXCL9 
• MIP-1α / CCL3 
• MIP-1δ / CCL15 
• MIP-3α / CCL20 
• MIP-3β / CCL19 
• MPIF-1 / CCL23 
• SCYB16 / CXCL16 
• SDF-1α+β / 
CXCL12 
• TARC / CCL17 
• TECK / CCL25 
• TNF-α 
Table 5. Biorad - Bio-Plex Pro Human Chemokine panel 40-plex 
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(Ct = threshold cycle of PCR at which the amplified product is detected). The ΔCt 
is the difference in Ct values derived from the gene of interest and the reference 
gene GAPDH; the factor 2^-ΔCt was used to express the ratio between the gene 
of interest and the internal reference gene. To rule out cross-contamination of 
reagents and primers, all RT, pre-amplification and real-time PCR experiments 
included an NTC sample, containing all the components of each reaction except 
for the template. Considering that 12 μl of pre-amplified cDNA were analysed for 
each transcript and that the available volume of each pre-amplified aliquot was 
250 μl, we were able to analyse in triplicate up to 20 transcripts. 
To check that all amplicons were amplified uniformly without bias, we performed 
pre-amplification uniformity experiments using non-limiting cDNA from a human 
non pathological pulmonary hilar lymph node (obtained from Dr. Egidio Stigliano, 
Institute of Pathological Anatomy, Policlinico A. Gemelli, Rome, Italy), as control 
for cellular genes. 
 
GAPDH CD8 Tbet CD4 FoxP3 
CD138 CD68 CD20 CD14  
IFN TNF LTa GM-CSF  
CXCL13 IL10 IL16 CXCL10 CCL8 
CCL3 CCL22    
Table 6. Gene expression panel 
 
3.5. Statistical analyses 
We analyzed demographic, clinical, MRI, CSF-protein array and gene expression 
data by univariate analyses for comparison between groups of patients (for 
continuous variables: Mann-Whitney test for non-parametric distribution or 
Student’s t test for parametric distribution, and by Fisher’s exact probability test 
for categorical variable). 
Pathway KEGG analysis was performed in order to identify pattern of 
proteins/genes involved in the same biological function. 
PhD Thesis   PhD Candidate: Dr. Dario Seppi 
 
43 
 
Correlation between variables was assessed by Spearman’s rank correlation 
coefficient.  
All statistical analyses were performed using GraphPad Prism 6 and R, an open 
source UNIX-based statistical package available at http://www.r-project.org. 
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4. Results 
 
In the MS Centre of Padova two independent cohorts of patients have been 
recruited and followed by a detailed neurological and clinical follow-up.  
The first cohort of MS patients,  composed of 35 patients and 5 controls was 
recruited retrospectively between February 2009 and September 2011 and 
analysed.  
The second cohort of 31 patients and 13 controls was collected prospectively 
from January 2014 to May 2015. The patients were at their disease onset or in 
the very early phase of the disease. No patient was previously treated with 
immunomodulant agents.  Each patient underwent a complete diagnostic work-
up comprehensive of clinical evaluation, lumbar puncture and MRI evaluation 
Here we provide the results of combined clinical, CSF and MRI investigation. 
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4.1. Combined MRI / CSF analysis of the first cohort of MS patients 
MRI analysis 
The extent of GM and WM involvement was quantified in 35 patients. CL number 
and CL volume were measured on DIR images and were respectively in MS 
patients: CL number 5,1±6,1 (range 0-21); CL volume 453±615,3 mm3 (range 0-
2500); Global cortical thickness (Cth) measured on 3D FFE sequences was 
2,38±0,15 mm (range 2,09-2,62). The observed volume of T2 WM lesions 
(T2WMLV) on FLAIR images was 1660,7±1922,2 mm3 (range 0-7600). Median 
number of spinal cord lesion was 1,8±2,2 (range 0-9) (Table 7). 
 
  CONTROLS (5 patients) CIS (22 patients) RR (13 patients) 
Age at LP (yr) 51,8±5,17 (43-56) 33,09±8,83 (16-49) 38,15±11,72 (21-57) 
M/F 1/4 10/12 4/9 
MRI a/o clinical signs of disease 
activiy 
n/a 11/22 5/13 
Disease duration at LP (months) n/a 2,59±4,37 (0-18) 6±4 (0-11) 
Days to 1st relapse [n pts/tot] n/a 
357,42±397,71 (15-1449) 
[19/22] 
330,44±378,86 
 (44-1162) [9/13] 
EDSS (median±mad) n/a 1,25±0,37 (1-2,5) 1,5±0 (1-2,5) 
Follow up (months) n/a 47,91±18,54 (13-80) 61,85±10,08 (40-76) 
Progression Index at FU n/a 0,08±0,35 (-0,92-1,12) 0,04±0,2 (-0,1-0,65) 
Disease form at FU(n/tot) n/a 3/35 32/35 
Time to conversion (days) n/a 82,16±127,97 (1-549) n/a 
Steroids in the month before LP n/a 3/22 1/13 
Shift to 2nd line therapy (n/tot) n/a 8/22 4/13 
SC.lesion number 0±0 (0-0) 1,95±2,09 (0-6) 1,69±2,43 (0-9) 
CL number 0±0 (0-0) 4,59±6,34 (0-21) 5,85±5,87 (0-18) 
CL volume (mm3) 0±0 (0-0) 393,14±604,3 (0-2500) 554,23±645,04 (0-2250) 
T2WMLV (mm3) - 
1658,82±2021,43 
 (0-7600) 
1663,85±1821,46 
(200-5800) 
Global.CTh (mm) 2,51±0,09 (2,43-2,61) 2,4±0,16 (2,11-2,62) 2,36±0,14 (2,09-2,59) 
Table 7. Clinical and MRI data from 1st cohort of patients. Data are expressed in mean ± SD 
(range), except for EDSS (median±mad). Abbreviations: LP lumbar puncture, yr year, CIS 
clinically isolated syndrome, RR relapsing remitting, SC spinal cord, CL cortical lesion, WML 
white matter lesion volume, Cth cortical thickness. Progression Index = (EDSS at FU – EDSS at 
LP)/yr of follow up. 
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CSF analysis 
By using the Bio-Plex System (Biorad - Bio-Plex Pro Human Chemokine panel 40-
plex) we performed a protein analysis of the presence and levels of inflammatory 
molecules in 35 MS patients compared to 5 controls included in the first cohort 
of the study. 
Preliminary analysis of the levels of cytokines and chemokines released in the 
CSF of MS cases (CIS and RRMS) and controls are shown in Table 8. 
 
 
 
 
CONTROLS (5 patients) CIS (22 patients) RR (13 patients) 
OCBs pos 0/5 21/22 12/13 
CSF Lymphocytes 
(number/uL) 
2,52±1,85 (0,7-5,5) 10,48±14,91 (1,7-70) 10,54±10,69 (0,7-38) 
Protein mg/mL 0,54±0,05 (0,47-0,61) 0,43±0,1 (0,29-0,7) 0,46±0,11 (0,32-0,69) 
IgGIndex 0,46±0,06 (0,41-0,55) 0,72±0,25 (0,46-1,43) 0,91±0,62 (0,4-2,7) 
X6Ckine.CCL21 648,78±226,35 (389,2-973,6) 
862,93±219,32 (587,17-
1247,37) 
720,38±209,54 (340,41-
1166,39) 
BCA.1.CXCL13 0,31±0,33 (0,02-0,81) 33,04±51,72 (0,05-206,01) 34,05±36,34 (1,09-116,61) 
ENA.78.CXCL5 121,27±84,9 (35,39-212,4) 154,91±81,67 (57,15-345,54) 130,37±81,36 (0-343,01) 
EOTAXIN.CCL11 9,48±1,84 (7,16-11,66) 9,57±1,71 (6,84-12,86) 8,79±1,91 (5,01-11,53) 
EOTAXIN.2.CCL24 21,53±2,92 (18,67-25,98) 30,11±5,74 (19,45-40,9) 28,23±7,32 (14,68-39,81) 
EOTAXIN.3.CCL26 7,23±0,71 (6,64-8,43) 11,13±1,89 (7,66-14,44) 10,2±2,59 (6,19-14,41) 
Fractalkine.CX3CL1 137,97±31,94 (100,66-177,61) 200,06±54,82 (125,57-289,43) 206,21±73,83 (88,97-321,81) 
GCP.2.CXCL6 0,97±0,93 (0-1,89) 1,31±1,49 (0-3,77) 2,06±2,37 (0-6,83) 
GM.CSF 66,09±13,75 (44,63-78,57) 100,81±18,8 (60,66-136,88) 94,87±20,54 (55,61-127,03) 
Gro.alpha.CXCL1 50,51±5,02 (43,4-54,94) 68,34±13,22 (41,97-89,36) 70,72±31,02 (39,7-155) 
Gro.Beta.CXCL2 3,88±2,65 (0-6,53) 9,79±3,58 (4,5-16,03) 8,14±3,58 (0-12,99) 
I.309.CCL1 15,75±1,8 (13,6-18,19) 26,86±6,83 (14,48-43,25) 25,39±6,71 (14,98-34,29) 
IFN.gamma 5,55±0,46 (4,86-6,09) 5,84±1,39 (3,69-8,55) 5,37±1,64 (1,66-7,95) 
IL.1beta 0,42±0,07 (0,32-0,53) 0,39±0,13 (0,26-0,67) 0,44±0,27 (0,03-1,22) 
IL.2 2±0,49 (1,62-2,8) 2,15±0,62 (1,22-3,33) 1,98±0,64 (0,95-2,94) 
IL.4 13,15±10,62 (1,91-24,83) 7,6±5,62 (1,77-27,86) 5,96±3,77 (1,1-13,88) 
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IL.6 7,4±1,81 (5,36-9,07) 17,43±21,54 (4,94-97,14) 9,85±4,58 (5,23-20,57) 
IL.8.CXCL8 49,44±11,04 (34,47-60,9) 86,11±39,63 (38,29-228,29) 87,74±54,9 (18,82-234,16) 
IL.10 6,58±2,01 (4,24-8,81) 8,7±3,05 (4,89-16,07) 7,99±3,21 (0-13,1) 
IL.16 62,78±13,13 (49,05-82,24) 47,03±20,96 (23,96-100,92) 46,07±21,15 (14,13-93,81) 
IP.10.CXCL10 469,74±185,83 (281-673,72) 
1181,3±1301,58 (249,21-
6552,26) 
982,72±684,15 (266,15-
2421,68) 
I.TAC.CXCL11 1,85±0,8 (1,04-2,74) 6,12±5,13 (1,61-19,64) 4,89±3,26 (1,03-11,51) 
MCP.1.CCL2 
791,84±280,74 (580,7-
1247,24) 
688,55±241,58 (278,03-
1461,72) 
616,51±244,64 (291,97-
1197,19) 
MCP.2.CCL8 11,58±3,54 (8,67-15,82) 20,19±14,81 (5,74-77,36) 14,83±7,99 (4,42-29,19) 
MCP.3.CCL7 6,81±2,21 (3,62-8,85) 6,65±2,58 (2,52-11,21) 6,08±3,46 (0-11,45) 
MCP.4.CCL13 1,38±0,2 (1,12-1,63) 2,29±0,62 (1,37-4,08) 2,01±0,54 (0,74-2,97) 
MDC.CCL22 27,3±11,76 (14,26-46,01) 73,89±53,55 (23,18-252,78) 85,45±50,45 (16,34-204,68) 
MIF 
6500,63±3379,21 (3632,45-
12137,56) 
24219,21±15059,11 (8013,62-
77459,79) 
24362,44±18677,39 
(3515,23-63478,97) 
MIG.CXCL9 17,27±3,19 (13,87-21,41) 37,02±24 (12,61-115,34) 33,56±13,76 (11,79-51,7) 
MIP.1alpha.CCL3 4,39±1,88 (2,69-7,47) 7,33±2,59 (4,79-15,89) 8±3,53 (2,83-15,39) 
MIP.1delta.CCL15 
534,79±174,66 (280,14-
772,38) 
626,78±176,36 (391,84-
1077,58) 
621,46±238,44 (143,29-
1218,12) 
MIP.3alpha.CCL20 0,75±0,11 (0,62-0,86) 0,96±0,22 (0,63-1,55) 0,98±0,37 (0,38-1,73) 
MIP.3beta.CCL19 70,4±15,78 (45,81-87,88) 219,81±208,82 (70,73-1120,83) 157,5±83,12 (33,53-324,02) 
MPIF.1.CCL23 8,1±3,72 (5,15-13,73) 13,36±4,17 (6,7-25,09) 11,68±6,05 (2,05-24,01) 
SCYB16.CXCL16 
1000,24±95,01 (933,84-
1143,84) 
1143,59±262,51 (640,97-
1550,63) 
1018,84±285,93 (676,39-
1494,36) 
SDF.1alpha.beta.CXCL12 
4001,85±826,62 (2924,54-
4891,42) 
3713,79±718,11 (2480,48-
5727,66) 
3478,1±1251,66 (897,75-
5183,56) 
TARC.CCL17 0,4±0,89 (0-1,99) 2,72±2 (0-7,84) 3,9±2,77 (0-8,92) 
TECK.CCL25 74,86±31,23 (43,88-117,4) 104,57±50,29 (45,65-274,35) 101,03±60,14 (0-220,55) 
TNF.alpha 23,43±12,88 (9,23-38,64) 24,3±8,18 (12,63-40,63) 23,63±9,12 (7,71-38,11) 
Table 8. Mean and SD of cytokines and chemokines released in the CSF of controls, CIS 
patients and RRMS patients. Abbreviations: OCB oligoclonal bands, CIS clinically isolated 
syndrome, RR relapsing remitting. Data are expressed in pg/mL 
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Statistic analysis has shown significantly higher CSF levels of CXCL13, CCL26, 
GM.CSF, CCL1, CXCL11, CCL13, CCL22 and CCL19 (and other molecules) in MS and 
lower levels of MIF (see Table 9) in MS patiens. 
 
 
MS patients (mean±sd) Controls (mean±sd) p-value 
Age (years) 34,97±10,14 (16-57) 51,8±5,17 (43-56) 0,0028** 
Lymphocytes 
(number/uL) 
10,5±13,33 (0,7-70) 2,52±1,85 (0,7-5,5) 0,02562* 
Protein (mg/mL) 0,44±0,1 (0,29-0,7) 0,54±0,05 (0,47-0,61) 0,02173* 
IgGIndex 0,79±0,43 (0,4-2,7) 0,46±0,06 (0,41-0,55) 0,00322** 
BCA.1.CXCL13 33,42±46,03 (0,05-206,01) 0,31±0,33 (0,02-0,81) 0,00006** 
EOTAXIN.2.CCL24 29,41±6,33 (14,68-40,9) 21,53±2,92 (18,67-25,98) 0,00487** 
EOTAXIN.3.CCL26 10,79±2,19 (6,19-14,44) 7,23±0,71 (6,64-8,43) 0,00191** 
Fractalkine.CX3CL1 202,34±61,56 (88,97-321,81) 
137,97±31,94 (100,66-
177,61) 
0,02099* 
GM.CSF 98,6±19,38 (55,61-136,88) 66,09±13,75 (44,63-78,57) 0,00191** 
Gro.alpha.CXCL1 69,23±21,19 (39,7-155) 50,51±5,02 (43,4-54,94) 0,01231* 
Gro.Beta.CXCL2 9,18±3,62 (0-16,03) 3,88±2,65 (0-6,53) 0,00739** 
I.309.CCL1 26,32±6,72 (14,48-43,25) 15,75±1,8 (13,6-18,19) 0,00018** 
IL.8.CXCL8 86,72±45,1 (18,82-234,16) 49,44±11,04 (34,47-60,9) 0,00676** 
IL.16 46,67±20,72 (14,13-100,92) 62,78±13,13 (49,05-82,24) 0,05262 
IP.10.CXCL10 1107,54±1105 (249,21-6552,26) 
469,74±185,83 (281-
673,72) 
0,02686* 
I.TAC.CXCL11 5,66±4,52 (1,03-19,64) 1,85±0,8 (1,04-2,74) 0,00191** 
MCP.4.CCL13 2,18±0,6 (0,74-4,08) 1,38±0,2 (1,12-1,63) 0,00025** 
MDC.CCL22 78,18±51,98 (16,34-252,78) 27,3±11,76 (14,26-46,01) 0,00098** 
MIF 
24272,41±16223,27 (3515,23-
77459,79) 
6500,63±3379,21 
(3632,45-12137,56) 
0,00098** 
MIG.CXCL9 35,74±20,63 (11,79-115,34) 17,27±3,19 (13,87-21,41) 0,00791** 
MIP.1alpha.CCL3 7,58±2,94 (2,83-15,89) 4,39±1,88 (2,69-7,47) 0,01067* 
MIP.3alpha.CCL20 0,97±0,28 (0,38-1,73) 0,75±0,11 (0,62-0,86) 0,02686* 
MIP.3beta.CCL19 196,67±174,08 (33,53-1120,83) 70,4±15,78 (45,81-87,88) 0,00191** 
MPIF.1.CCL23 12,74±4,94 (2,05-25,09) 8,1±3,72 (5,15-13,73) 0,04735* 
TARC.CCL17 3,16±2,35 (0-8,92) 0,4±0,89 (0-1,99) 0,00673** 
Table 9. Differences in CSF biomarkers between MS population and Controls. Data are 
expressed as mean ± SD. CSF citokines and chemokines values are expressed in pg/mL. 
p<0,05= *; p<0,01= **. 
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The MS study population was stratified in two subgroups according to low and 
high GM pathology [cortical lesion number cortical lesion volume/number (CL 
volume, cut-off 185mm3 (median value); CL volume low: n=18, CL volume high 
n=17); Global cortical thickness (Cth, cut-off 2,42 mm; Cth low: n=18, CL high 
n=17), and to T2 white matter lesion volume (T2WMLV, cut-off 1000 mm3; 
T2WMLV low: n=18, T2WMLV high .n=17). The two groups did not differ by sex, 
age at lumbar puncture, disease duration and EDSS. 
MS patients with low CLs number or CL volume have significantly higher (p<0,05) 
CSF levels of CCL7, MIF, CXCL6 and CCL25 and a trend (p=0,05) for CXCL9 and 
CCL19 compared to patients with high CLs number or CL volume (Figure 4).  
Figure 4. Boxplot representing different concentrations (pg/ml) of CCL25, MIF, CCL7 and 
CXCL6  (p<0.01), and CCL19, CXCL9 (p=0,05) in patients with high or low CL volume. 
Abbreviations: CL cortical lesion. CSF citokines and chemokines values are expressed in 
pg/mL 
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Patients with higher T2 white matter lesion volume (T2WMLV) values, indicating 
the load of white matter damage, have higher CSF levels of GM-CSF and lower 
CSF levels of CXCL9, CXCL11, CXCL13, CXCL6, CCL7, CCL17 compared to patients 
with lower T2WMLV (Figure 5). 
 
 
 
Figure 5. Patients with lower T2 white matter lesion volume (T2WMLV) express higher 
concentration of CCL7, CCL17, CCL25, CXCL9, CXCL11, CXCL13, CXCL6 and lower 
concentration of GM.CSF (p < 0.05) compare to patients with higher T2WMLV. CSF 
citokines and chemokines values are expressed in pg/mL 
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Patients with lower cortical thickness (Cth) values, characterizing cortical 
atrophy, express lower value of CCL7 and CXCL12 compared to patients with 
higher cortical thickness (Figure 6). 
 
 
 
 
Figure 6. Patients with lower cortical cortical thickness (Cth) values express lower value 
of CCL7 and CXCL12 compared to patients with higher Cth. CSF citokines and 
chemokines values are expressed in pg/mL. 
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Patient with absence of disease activity, measured as presence of Gd+ MRI lesion 
and/or concomitant relapsing phase, show significant higher level of IL4 and a 
trend (p=0,05) of higher level of Interferonn gamma (IFNg) (Figure 7).  
 
Figure 7. Disease activity (“0”= absence, “1”= presence); patient without signs of disease 
activity showed high level of IL4 (p<0,05)and Interferon gamma (IFNg) (p=0,05). CSF 
citokines and chemokines values are expressed in pg/mL   
 
Correlation analysis. There were no significant correlation between MRI 
measures and other related clinical and CSF data, except for a good correlation 
between disease duration and time to conversion (rho di Spearmen 0.95 
p<0.0001) in CIS MS population. 
 
Correlations between CSF cytokines revealed in MS patients are summarized in 
Figure 8  where a correlation matrix of the protein investigated in the cohort of 
MS patients is displayed. Correlation coefficients are between plus 1 and minus 1 
corresponding to different colors whose value are explain in the color legend. 
Black squares identify cluster of aggregation between protein molecules. 
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Figure 8. Correlation matrix of investigated CSF cytokines and chemokines. The results 
are grouped accordingly cluster analysis “ward” (black squares).  
 
 
4.2. Combined MRI/CSF analysis of the second cohort of MS patients 
MRI analysis 
CL Number and CL Volume were measured on DIR Images and were respectively: 
CL Number 3,58±4,193 (range 0-16); CL Volume 103,1±233,7 mm3; Global 
Cortical thickness was 2,575±0,134 mm, GMF was 0,545±0,024 (ratio). The 
observed volume of T2 WM Lesions (T2WMLV) on FLAIR images was 
2617,7±3253,6 mm3 (range 59,26-13530,5). Median number of spinal cord lesion 
was 1,48±1,95 (range 0-7). Gadolinium enhancing lesion (Gd+) number was 
0,452±0,961 (range 0-5) (Table 10). 
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CONTROLS (13 patients) CIS (12 Patients) RR (19 Patients) 
Age at LP (years) 42,92±10,31 (29-60) 33,5±10,87 (22-50) 37,89±8,48 (18-50) 
M/F 2/13 3/12 10/19 
Disease duration at LP (months) 31,15±68,88 (0-255) 10,08±19,55 (0-69) 21,42±32,52 (0-136) 
MRI a/o clinical signs of disease 
activity (n/tot) 
0/13 2/12 9/19 
EDSS (median±mad) n/a 1,5±0,74 (0-2) 1,5±0,74 (0-3,5) 
SC lesion number 0±0 (0-0) 0,92±0,9 (0-3) 1,84±2,34 (0-7) 
Gd + lesion n 0±0 (0-0) 0,08±0,29 (0-1) 0,68±1,16 (0-5) 
T2WMLV (mm3) 
1670,15±1706,73 
(317,89-5857,54) 
1988,86±3515,55 
(59,26-12320,4) 
3015,27±3076,54 
(524,55-13530,5) 
CL number 0±0 (0-0) 2,08±2,97 (0-11) 4,53±4,64 (0-16) 
CL volume (mm3) 0±0 (0-0) 41,79±97,5 (0-345,74) 141,82±284,88 (0-1260,68) 
Cth (mm) 2,61±0,11 (2,43-2,82) 2,63±0,07 (2,49-2,73) 2,54±0,15 (2,27-2,77) 
Cortical ratio 0,4±0,02 (0,38-0,43) 0,4±0,02 (0,36-0,43) 0,39±0,02 (0,37-0,45) 
GMF 0,55±0,01 (0,53-0,57) 0,55±0,02 (0,51-0,59) 0,54±0,03 (0,51-0,61) 
Altered VEP/tot 2/13 5/11 7/18 
Table 10. Clinical and MRI data from 2nd cohort of patients. Data are expressed in mean ± SD 
(range), except for EDSS (median±mad). Abbreviations: LP lumbar puncture, n number, CIS clinically 
isolated syndrome, RR relapsing remitting, SC spinal cord, CL cortical lesion, WML white matter 
lesion volume, Cth Global cortical thickness, GMF grey matter fraction, Visual evoked potential. 
 
CSF analysis (protein and gene expression analysis)  
We performed a detailed protein analysis using the Bio-Plex System in order to 
detect the presence and levels of 40 inflammatory molecules expressed in the 
CSF of the 31 MS patients compared to the 13 controls recruited in the current 
study.  
 
Preliminary analysis of cytokines and chemokines released in the CSF of MS cases 
(CIS and RRMS) and controls are shown in Table 11.  
Gene expression data of immune related genes in CSF cells of CIS patients and 
RRMS patients are summarized in Table 12. 
 
 
CONTROLS (13 patients) CIS (12 Patients) RR (19 Patients) 
OCB positive 0/13 7/12 16/19 
IgG index 0,47±0,06 (0,4-0,61) 0,68±0,33 (0,32-1,48) 0,86±0,63 (0,38-3,2) 
Protein mg/mL 0,29±0,1 (0,14-0,49) 0,31±0,07 (0,17-0,41) 0,32±0,13 (0,19-0,65) 
CSF - cell number/uL 2,17±1,3 (0,3-5,5) 7,94±11,64 (1-43) 8,78±12,55 (1,7-58) 
6Ckine/CCL21 
2597,27±1508,56 (915,03-
6475,57) 2981,17±1339 (1663,87-6234) 
3346,97±1993,81 (1363,6-
9482,36) 
BCA-1/CXCL13 0,71±0,59 (0-1,7) 17,47±41,7 (0-148,15) 29,2±31,01 (0,68-122,48) 
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ENA-78/CXCL5 
228,54±131,51 (64,12-501,69) 
295,17±176,64 (150,71-
756,41) 352,99±176,91 (108,52-704,4) 
EOTAXIN/CCL11 27,59±12,47 (13,27-52,94) 31,18±13,69 (21,68-71,71) 37,46±20,52 (14,45-107,11) 
EOTAXIN-2/CCL24 92,8±61,07 (23,67-217,64) 88,5±33,17 (51,96-174,76) 109,47±84,01 (0-414,32) 
EOTAXIN-3/CCL26 29,61±19,15 (8,93-81,5) 27,94±11,88 (10,3-54,24) 33,05±23,38 (3,43-117,57) 
Fractalkine/CX3CL1 
360,53±115,3 (207,48-586) 
367,47±116,25 (227,44-
587,18) 436,03±307,15 (78,98-1325,61) 
GM-CSF 143,98±83,32 (0-327,5) 133,71±41,62 (89,32-239,94) 151,38±108,3 (58,92-541,07) 
Gro-alpha/CXCL1 124,09±58,01 (67,38-265,29) 118,4±31,34 (90,59-196,53) 143,81±93,43 (56,27-482,68) 
Gro-Beta/CXCL2 20,83±17,02 (0-50,64) 19,27±26,82 (0-95,61) 25,47±14,92 (0-59,11) 
I-309/CCL1 70,07±40,9 (20,17-158,36) 81,84±24,48 (55,59-133,35) 100,67±55,8 (48,55-301,93) 
IFN-gamma 14,23±6,34 (6,83-31,21) 13,73±4,96 (7,93-24,52) 15,7±11,85 (4,02-61,21) 
IL-1beta 0,55±0,22 (0,31-0,96) 0,43±0,31 (0-1,21) 0,49±0,49 (0-2,43) 
IL-2 4,06±1,35 (2,05-6,43) 3,53±1,67 (1,48-8,09) 3,97±2,73 (1,22-14,36) 
IL-4 19,38±17,74 (3,53-65,13) 25,59±24,54 (5,43-95,65) 27,03±17,55 (4,88-59,67) 
IL-6 13,1±4,24 (8,88-21,79) 13,86±12,56 (6,58-52,67) 24,78±28,74 (2,65-109,32) 
IL-8/CXCL8 75,24±29,73 (31,89-139,07) 75,94±25,63 (49,15-129,35) 88,4±39,33 (38,11-177,39) 
IL-10 11,71±3,59 (7,87-19,63) 10,88±3 (7,68-17,94) 13,67±7,7 (4,43-41,71) 
IL-16 123,45±47,91 (70,62-245,29) 142,17±70,6 (51,15-264,97) 158,65±91,18 (33,2-443,96) 
IP-10/CXCL10 
744,61±347,78 (393,8-
1592,19) 
1031,91±441,57 (409,44-
1865,88) 
1484,82±757,1 (599,07-
3219,53) 
I-TAC/CXCL11 4,61±1,99 (1,69-8,5) 7,42±4,1 (3,32-17,47) 10,5±6,32 (3,61-25,73) 
MCP-1/CCL2 
1113,91±367,1 (524,55-
1703,14) 
685,89±281,45 (251,73-
1186,95) 
1016,72±1024,04 (170,04-
4698,18) 
MCP-2/CCL8 18,15±4,27 (12,73-29,29) 21,01±7,68 (9,26-32,05) 38±27,81 (11,2-131,71) 
MCP-3/CCL7 15,03±6,09 (6,7-31,04) 17,35±19,78 (0-73,12) 18,24±15,07 (0-75,86) 
MCP-4/CCL13 4,18±2,23 (1,74-9) 4,75±1,25 (3,08-6,91) 5,5±3,17 (2,05-16,96) 
MDC/CCL22 40,94±16,34 (13,59-76,07) 58,68±45,07 (20,44-188,46) 80,67±38,05 (35,65-155,15) 
MIF 
22430,55±18582,96 (2912,63-
74856,36) 
21159,44±11464,92 (4790,8-
39936,53) 
21808,52±23959,29 (5451,74-
115563,93) 
MIG/CXCL9 45,58±26,17 (20,02-117,73) 56,29±29,09 (23,19-116,71) 81,37±58,07 (21,51-262,71) 
MIP-1alpha/CCL3 5,75±1,81 (2,66-9,48) 7±3,07 (3,63-13,23) 9,08±4,81 (3,14-22,29) 
MIP-1delta/CCL15 
783,3±354,35 (398,9-1592,77) 
560,08±191,79 (360,59-
921,05) 672,08±549,01 (215,94-2807,5) 
MIP-3alpha/CCL20 2,16±1,07 (1,07-4,71) 2,36±1,02 (1,19-4,58) 2,7±1,53 (0,69-8) 
MIP-3beta/CCL19 155,91±53,99 (91,6-275,79) 200,44±83,35 (93,9-338,95) 245,9±188,28 (68-939,11) 
MPIF-1/CCL23 14,6±5,58 (7,88-26,25) 14,56±4,85 (6,48-21,27) 16,77±11,02 (5,4-53) 
SCYB16/CXCL16 
2068,01±775,76 (1002,08-
3666,19) 
1774,93±387,88 (1331,03-
2499) 
2220,68±1538,21 (621,51-
7667,75) 
SDF-
1alpha+beta/CXCL12 
6226,59±1742,04 (4130,88-
10697,64) 
5654,05±1488,43 (3484,19-
8187,41) 
6819,24±5931,34 (1772,1-
29784,75) 
TARC/CCL17 0,88±1,4 (0-3,59) 2,34±5,83 (0-20,21) 2,57±3,56 (0-12,29) 
TECK/CCL25 351,06±248,24 (79,5-952,21) 385,1±161,98 (211,39-779,82) 421,2±309,66 (151,63-1636,32) 
TNF-alpha 42,41±41,8 (17,1-173) 46,32±30,92 (13,97-120,12) 54,6±32,18 (19,06-119,86) 
Table 11. Mean and SD of cytokines and chemokines released in the CSF of control patients, 
CIS patients and RRMS patients. Abbreviations: OCB oligoclonal bands, CIS clinically isolated 
syndrome, RR relapsing remitting. CSF cytokines and chemokines values are expressed in 
pg/mL.   
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CONTROLS (13 patients) CIS (12 Patients) RR (19 Patients) 
CCL22 0,06±0,06 (0-0,18) 0,04±0,03 (0-0,11) 0,03±0,03 (0-0,09) 
CCL3 18,76±18,36 (0,57-47,5) 30,87±43 (0,53-135,02) 33,24±30,48 (1,52-96) 
CCL8 0,11±0,08 (0-0,27) 0,03±0,03 (0-0,07) 0,07±0,08 (0-0,21) 
CD138 0±0 (0-0) 0±0 (0-0) 0,01±0,01 (0-0,03) 
CD14 22,84±20,89 (4,23-69,36) 28,48±38,24 (4,5-114,09) 26,99±21,97 (2,55-67,6) 
CD20 0,01±0,01 (0-0,04) 0,11±0,23 (0-0,77) 0,22±0,4 (0-1,38) 
CD4 5,15±4,97 (0,06-14,06) 2,55±2,36 (0,45-8,73) 2,01±1,28 (0,06-4,69) 
CD68 3,45±2,21 (0,78-8,87) 2,3±2,09 (0,9-6,93) 2,08±1,73 (0,13-6,41) 
CD8 0,35±0,35 (0-1) 0,8±1,15 (0,06-3,99) 1,05±1,23 (0-3,96) 
CXCL10 0,01±0,02 (0-0,06) 0,01±0,01 (0-0,02) 0,01±0,01 (0-0,02) 
CXCL13 0±0,01 (0-0,02) 0,04±0,12 (0-0,39) 0±0,01 (0-0,03) 
FoxP3 0,04±0,07 (0-0,26) 0,07±0,14 (0-0,49) 0,2±0,17 (0-0,55) 
GAPDH 1±0 (1-1) 1±0 (1-1) 1±0 (1-1) 
GM-CSF 0±0 (0-0) 0±0,01 (0-0,02) 0±0,01 (0-0,02) 
IFN 0±0 (0-0,02) 0,01±0,02 (0-0,06) 0,01±0,01 (0-0,03) 
IL10 0,27±0,28 (0-0,87) 0,07±0,04 (0-0,15) 0,13±0,11 (0-0,32) 
IL16 0,41±0,27 (0,09-1,01) 0,82±0,74 (0,24-2,84) 1,03±0,98 (0,04-2,96) 
LTa 0±0,01 (0-0,05) 0,01±0,01 (0-0,05) 0,03±0,03 (0-0,11) 
Tbet 0,03±0,04 (0-0,14) 0,11±0,13 (0-0,4) 0,16±0,17 (0-0,51) 
TNF 0,48±0,47 (0-1,44) 0,13±0,15 (0,01-0,51) 0,25±0,28 (0-0,87) 
Table 12. Expression of immune related genes in CSF cells CIS patients and RRMS 
patients.  Gene expression values are presented as -2^∆Ct relative to GAPDH and are 
expressed as median ± SD. 
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Statistic analysis by using Mann Whitney signed rank test shows high significantly 
different levels (p<0,01) of different CSF protein as CXCL13, CXCL10, CXCL11, and 
CCL22, and high significantly different levels (p<0.01) in gene-expression of 
Lymphotoxin-alpha (LTa) and T-box transcription factor TBX21 (Tbet), and 
significant different (p<0,05) levels in gene-expression of in CCL8, CD138, CD20, 
CD68, CXCL13, FoxP3 and IFNg in MS patients compared to controls patients. 
Results are summarized in Table 13. 
 
Control SM patients p-value 
IgG index 0,47±0,06 (0,4-0,61) 0,79±0,54 (0,32-3,2) 0,0009** 
CSF cell number/uL 2,17±1,3 (0,3-5,5) 8,46±12,02 (1-58) 0,0018** 
BCA-1/CXCL13 0,71±0,59 (0-1,7) 24,66±35,33 (0-148,15) 0,00002** 
IP-10/CXCL10 744,61±347,78 (393,8-1592,19) 1309,5±682,42 (409,44-3219,53) 0,0005** 
I-TAC/CXCL11 4,61±1,99 (1,69-8,5) 9,31±5,7 (3,32-25,73) 0,0011** 
MCP-1/CCL2 1113,91±367,1 (524,55-1703,14) 888,66±827,69 (170,04-4698,18) 0,0192* 
MCP-2/CCL8 18,15±4,27 (12,73-29,29) 31,42±23,59 (9,26-131,71) 0,0104* 
MDC/CCL22 40,94±16,34 (13,59-76,07) 72,16±41,62 (20,44-188,46) 0,0066** 
MIG/CXCL9 45,58±26,17 (20,02-117,73) 71,66±49,88 (21,51-262,71) 0,0598* 
MIP-1delta/CCL15 783,3±354,35 (398,9-1592,77) 628,73±444,3 (215,94-2807,5) 0,0438* 
CCL8 0,11±0,08 (0-0,27) 0,05±0,06 (0-0,21) 0,0285* 
CD138 0±0 (0-0) 0,01±0,01 (0-0,03) 0,0485* 
CD20 0,01±0,01 (0-0,04) 0,17±0,33 (0-1,38) 0,0185* 
CD68 3,45±2,21 (0,78-8,87) 2,18±1,87 (0,13-6,93) 0,039* 
CXCL13 0±0,01 (0-0,02) 0,02±0,08 (0-0,39) 0,0178* 
FoxP3 0,04±0,07 (0-0,26) 0,14±0,17 (0-0,55) 0,044* 
IFN 0±0 (0-0,02) 0,01±0,01 (0-0,06) 0,0124* 
LTa 0±0,01 (0-0,05) 0,02±0,03 (0-0,11) 0,0023** 
Tbet 0,03±0,04 (0-0,14) 0,14±0,15 (0-0,51) 0,0085** 
    
Table 13. Differences in CSF protein (first box) and gene expression (second box) 
between MS population and controls. CSF cytokines and chemokines values are 
expressed in pg/mL  Gene expression values are presented as -2^∆Ct relative to GAPDH. 
The relative amount expressed as median ± SD. Comparison was made by Mann 
Whitney signed rank test.p<0,05= *; p<0,01= **. 
 
By stratifying the study population in two subgroups according to high and low 
cortical lesion volume (CL number, cut-off: median value; CL volume low: n=16, 
CL volume High n=15) and Cth (Cth, cut-off: median value ; Cth low: n=16, CL 
High n=17) and T2 white matter lesion volume (T2WMLV, cut-off: median value; 
T2WMLV low: n=16, T2WMLV High n=15) it was found that MS patients with 
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higher CL volume are characterized by higher level of CSF cell number, Gd+ 
lesions and T2WMLV compared to patients with lower CL volume. They have 
significantly (p<0.05) higher CSF protein levels of CXCL13 and higher values of 
gene expression of CD138 and GM-CSF and a trend (p=0.05) for CD20 compared 
to patients with lower CL volume(see Figure 9) 
 
Figure 9. Patients with higher CL volume express higher value of A) CSF cell number, 
Gadolinium enhancing lesion (Gd+) number, and T2WMLV volume (mm3) B) CXCL13 
protein values C) values of gene expression of CD138 and GMCSF and a trend for CD20 
compared to patients with lower degree of CL volume. CSF cytokines and chemokines 
values are expressed in pg/mL. Gene expression values are presented as -2^∆Ct relative 
to GAPDH and are expressed as median ± SD. 
  
A
) 
B
) 
C
) 
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MS patients with higher T2WMLV (mm3) are characterized by higher number of 
CL volume (mm3), higher level of IgG Index and  CXCL11 protein in the examined 
CSF (see Figure 10) 
 
 
Figure 10. Patients with higher value of T2WMLV present higher value of cortical lesion 
(CL) volume(mm3), higher level of IgG Index and higher level of CXCL11 compared to 
patients with lower value of T2WMLV. CXCL11 values are expressed in pg/mL   
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Patients with lower Cth values have lower CSF protein levels of CCL21, CCL24, 
CXC3CL1, CXCL1, CCL2, CCL13 and CXCL16 compared to patients with higher 
values of Cth (Figure 11). 
 
 
Figure 11. Patients with lower Global cortical thickness (Cth) present lower value of 
CCL21, CCL24, CXC3CL1, CXCL1, CCL2, CCL13 and CXCL16 compared to patients with 
higher values of Cth. CSF cytokines and chemokines values are expressed in pg/mL . 
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Patient with clinical and MRI evidence of disease activity have significantly higher 
levels of CLs number, higher CSF levels of IgG Index, CXCL13, CXCL10, CXCL11, 
CCL8, CCL22, CCL3 compared to patients without any clinical and radiological 
evidence of disease activity (Figure 12). 
 
Figure 12. Patients with higher disease activity show higher value of A) spinal cord lesion 
number and CL number and higher level of IgG Index B) higher protein level of CXCL10, 
CXCL13, CXCL11, CCL 22 and CCL3. CSF cytokines and chemokines values are expressed 
in pg/mL. 
  
A
) 
B
) 
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5. Discussion 
Our study shows that cortical pathology, as revealed by advanced MRI 
methodology,  positively correlate with CSF bio-markers of intrathecal 
inflammation, in particular associated with  B-cell response since early disease 
stage.  
This finding strongly corroborate the hypothesis of a key role of meningeal 
inflammation in cortical pathology, as previously suggested by several 
neuropathological studies on post-mortem and bioptic MS tissues (Magliozzi et 
al., 2007, 2010; Howell et al., 2011; Lucchinetti et al., 2011). 
Soluble factors secreting from meningeal inflammatory aggregates, populated by 
infiltrating B-cells, plama cells, CD4+ and CD8+ positive cells, have been 
suggested to promote a gradient of demyelination and neuronal injury in the 
cortical grey matter bathed by the CSF flow (Magliozzi et al., 2010; Gadner et al., 
2013). The extent of meningeal inflammation indeed associates positively with 
cortical demyelination and disease progression, suggesting that chronic immune 
activity in the subarachnoid compartment plays a key role also from the early 
disease stage (Lucchinetti et al., 2011).  
Furthermore, elevated IgG index and the presence of OCBs, which represent an  
extremely useful CSF marker of intrathecal chronic humoral immunity in MS may 
be hypothesised to be in somehow linked to the presence of compartmentalized 
intrathecal B-cell response,   possibly within ectopic B-cell follicles structures 
settled in the subarachnoid space. 
Concomitant MRI studies in the last decade have emphasized the relevance of 
cortical pathology, which occur at the earliest phase of MS, on clinical and 
physical disability (Calabrese et al., 2010). 
For this reason in attempt to investigate how cortical pathology in vivo could be 
related to intrathecal inflammation, possibly related to the presence of 
meningeal infiltrates, we performed a combined analysis by using non-
conventional MRI sequences and molecular CSF analysis. In particular we carried 
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out a protein analysis of 40 cytokines and chemokines in the CSF and a gene 
expression analysis of the matched cellular fraction.  
We firstly investigated the contribution of MRI data and CSF molecular analysis 
characterizing MS patients from control.  
Hereafter MRI parameters of GM damage were adopted to stratify patients 
having more severe cortical pathology and to find possible inflammatory 
mediators linked to higher or lower degree of cortical lesion load. 
In the first cohort we observed that MS patients were characterized with higher 
rate of cortical atrophy than controls. Under the investigated molecules, the 
significantly overexpressed in the CSF of MS patients compared to controls were 
CXCL13 (p=0,00006), CCL19 (p=0,0019), CCL1 (p=0,00018), and CCL22 (0.0009),  
suggesting that the CSF of MS patients represent an inflammatory milieu with 
potential key role in the pathogenesis of the disease.  
In line with previous studies we revealed an increase of CXCL13 a potent B-cell 
attracting chemokine and a CSF promising biomarker indicative of the humoral 
immune response in CNS. In the current study, this chemokine, although it is not 
disease specific, because is related to several other chronic inflammatory 
diseases, is increased in active patients, is present in early MS and finally is 
associated with higher risk to conversion to definite MS. Furthermore it has been 
proposed as a potential biomarker to assess therapeutic effects on intrathecal 
inflammation of B-cell depleting therapies as rituximab (Piccio et al., 2010). It 
was recently demonstrated that CXCL13 is not essential in mounting effective 
peripheral humoral responses, but specifically promotes CNS accumulation of 
differentiated B cells (Phares et al., 2016), suggesting that overexpressed protein 
levels in the CSF of MS patients may have an important role in the accumulation 
of B cells in the CNS of affected patients since the disease onset as well as in the 
perpetuation of the humoral response during the chronic stage.  
Indeed CXCL13, together with CCL19, is reduced after rituximab treatment, an 
anti CD20 therapy that has been reported to have also some efficacy on disease 
progression (Hauser 2008). CCL19 bind to receptor CCR7 and its transcripts were 
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found in both active and inactive MS lesions.  Elevated levels were already 
detected in the CSF of MS patients and were correlated with higher level of IgG 
production (Krumbolz et al., 2007). CCL19 may also play both a physiological 
immunosurveillance and pathological role. 
Regarding CCL1 and CCL22 these chemokines are involved in Th2 response, Th2 
cell migration, and Treg migration. However their role have been less 
investigated yet in multiple sclerosis. Galimberti and coll. attribute to CCL22, 
which is secreted by dendritic cells and macrophages, a role, in females, in the 
development of a lesser severe type of MS through recruitment of Th2 cells 
(Galimberti et al., 2009).  However CCL22 promotes, through the receptor CCR4 
the recruitment of circulating memory T cells (Th0) which, depending on the CNS 
milieu, have the ability to differentiate into Th1 and Th2 and acquire either a pro- 
or anti-inflammatory phenotype.  
In order to better understand the role of these cytokines we stratify our first 
cohort according to GM and WM damage and we surprisingly observed an 
increment of pro-inflammatory chemokines in patients with lower GM and WM 
damage without recognising common immunological pathway. Furthermore 
stratifying according to disease activity we disclosed only a modest decrease of 
cytokine IL4.  It has to be mentioned that not proper procedures of CSF storing 
have been followed during the recruitment of this first cohort of patients.  
Therefore, further analysis of the results of our first retrospective cohort has 
shown some critical steps and results has to be interpreted with caution.  
Methodologies has been also implemented and criteria of selection have become 
more stringent for our second prospective cohort. The interpretation of the data 
of the first cohort has been taken in consideration only by high rate of 
significance. Moreover follow up analysis has not been showed for lack of 
significance and because the small sample size and the variety of therapies 
adopted from MS patients has not allowed to interpret our data correctly.  
On the second cohort preliminary protein analysis pointed out an important 
increase of CXCL13 in MS population compared to controls. Moreover we found 
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a relevant increase of CXCL10, CXCL11 and CCL22.  CXCL10 and CXCL11 are 
responsible for Th1 response and for Th1, CD8, Natural Killer (NK) cells 
trafficking. In particular, IFNg induced CXCL10 together with CXCR3 (its receptor) 
and has a crucial role in the accumulation of T cells in the CNS of MS patients and 
positively correlate with cell count (Sørensen et al., 2002). Once again we 
revealed an increase of CCL22 chemokine. Its moderate correlation with levels of 
CXCL10, and CCL8 and a higher correlation with gene expression of FoxP3 
suggest a potential role in  T cell trafficking regulatory role in particular during 
disease activity. Also CXCL10 is more expressed during activation phases of MS. 
We can speculate that BBB disruption in active phase of the disease may alter 
the subtle balance of cell trafficking. 
On the second cohort data analysis was also improved introducing a relative 
simple procedure in order to perform large gene expression analysis, thus 
allowing a better understanding of immunopathological mechanisms in MS. 
Based on the experience of a previous work which explored the reliability of pre-
amplification real-time reverse-transcription polymerase chain reaction (PreAmp 
RT-PCR) to analyze expression of  different genes (Veroni et al., 2015), we 
explore the expression of 20 immune related genes together with protein array 
analysis.   
The most interesting data, after stratification according to GM pathology, 
revealed once again a significant increase of CXCL13 protein. Noteworthy gene 
expression analysis in MS patients also reveals a significant difference in MS 
patients for CD20, CD138 and LTa supporting the role of a B-cell response and 
lymphoid neogenesis in MS pathology. All these molecules and cells play a 
relevant role in fact in the organization and activity of secondary and tertiary 
lymphoid organs (Aloisi, 2001). 
However patients with higher level of CL volume are not characterized by higher 
expression of CXCL13. This combined analysis may indicate that the source of 
this cytokine should not be sought in CSF cells but probably mostly in the 
meninges resident inflammatory cells. These data confirm the role of CXCL13 in 
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B-cell trafficking, but more surprisingly the impact on GM pathology expressed as 
CL volume.  
Interestingly, when stratifying for Cth we observed (with higher statistically 
significance, p= 0,001) higher level of CCL2 related to higher value of Cth which 
may suggest a possible protective role of this cytokine, thus suggesting that 
cortical atrophy may be influenced by altered balance of pro and anti -
inflammatory cytokines. In a precedent study Sørensen and coll. observed that 
CCL2 negatively correlates with measures of inflammation (Sørensen et al., 
2001). However this results are in contrast with those conducted recently on 
animal model where lack of CCL2 and CCL3 correlate with less severe 
demyelination (Janssen et al., 2015).  
In conclusion, combined CSF analysis and MRI analysis suggest that B cell 
immune response plays an important role in MS since the disease onset and 
correlates with the level of intrathecal inflammation . A more detailed analysis of 
the CSF biomarkers suggested in the current study might provide, in addition to 
MRI optimization, a better indication of severity of disease process that 
characterized GM pathology and important tools in predicting/monitoring the 
evolution of the disease in order to choose the most adequate and aggressive 
therapeutic strategies in those patients at higher risk to develop clinical and 
cognitive disability in shorter time. Finally, anti B-cell depleting strategies seems 
to be a promising option in slowing down GM damage. 
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